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An expert is a person who has found out by his own 
painful experience all the mistakes that one can make in a 
very narrow field. 
Niels Bohr 
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ABSTRACT 
Carbohydrates are ubiquitous on the surface of all cells in mammals where they are 
involved in interactions with the surroundings (extracellular matrix), other cells 
(including self and non-self) and microbes (bacteria and virus). Carbohydrate-protein 
interactions in nature are often mediated via multivalent binding where the combined 
strength of multiple receptor-ligand interactions results in a binding that is highly 
specific and strong. 
In this thesis we have produced proteins that are densely decorated with carbohydrate 
determinants in order to study the glycosylation capacity of cell lines (paper I) and 
generate efficient binders of antibodies (paper II), bacterial toxins (paper III) and virus 
receptors such as the influenza hemagglutinin (paper IV). 
P-selectin glycoprotein ligand-1 (PSGL-1) is a mucin-type protein that is heavily 
substituted with O-glycans. PSGL-1 genetically fused to mouse IgG2b Fc forms a 
dimeric PSGL-1/mIgG2b mucin-type fusion protein. 
In paper I, PSGL-1/mIgG2b was produced in Sf9 (Spodoptera frugiperda) and Hi-5 
(Trichoplusia ni) cell lines. The mucin-type protein was used as a probe to analyze the 
O-glycosylation capacity of these cell lines, which today are used for the commercial 
production of recombinant proteins and vaccine components. Liquid chromatography-
mass spectrometry (LC-MS) revealed that the O-glycosylation was more abundant and 
complex than previously reported which may limit their use for the production of 
therapeutic proteins.  
The glycosylation of PSGL-1/mIgG2b may be tailored by producing the protein in 
genetically engineered cell lines. Rational glycan design is achieved by transfecting 
cells with plasmids encoding PSGL-1/mIgG2b together with specific 
glycosyltransferases that expand the glycosylation capacity of the cells. 
In paper II, genetically engineered Chinese Hamster Ovary (CHO) cells were used to 
produce PSGL-1/mIgG2b carrying blood group A and B determinants on type 1, 2 and 3 
outer core saccharide chains. The multivalent mucins could adsorb chain type-specific 
anti-A antibodies, which indicate a prospective use of the mucins in immunoadsorption 
(IA) columns. IA columns are used to remove anti-A and anti-B reactive antibodies 
prior to organ transplantation across the blood group ABO barrier. 
In paper III and IV, genetically engineered CHO cells were used to produce high 
affinity binders of Shiga toxin 1 and 2 (Stx1 and Stx2) and avian influenza 
hemagglutinin (H5). Biacore biosensor assays indicated that PSGL-1/mIgG2b carrying 
the blood group P1 determinant in multiple copies bound with high affinity to Stx1 and 
Stx2, while PSGL-1/mIgG2b presenting multiple copies of Siaα2,3Gal on different O-
linked cores bound with high affinity to avian influenza H5. It remains to be shown if 
PSGL-1/mIgG2b can competitively inhibit and sterically block toxin and viral 
attachment to the cell surface. 
In conclusion, PSGL-1/mIgG2b carrying specific carbohydrates is a versatile tool that 
can be used in a range of applications where the multivalency confers a biologically 
relevant binding.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Celler är rikligt dekorerade med socker på sin yta. Dessa socker är viktiga för cellens 
kommunikation med sin omgivning (extracellulär matrix), andra celler (kroppsegna och 
främmande) och mikroorganismer (bakterier och virus). Protein-socker bindningar i 
biologiska system förmedlas ofta via bindning där flera receptor-ligand par tillsammans 
bidrar till en stark och specifik bindning (multivalens). I denna avhandling har vi med 
hjälp av genmodifierade celler producerat proteiner som är rikligt dekorerade med 
sockerkedjor (glykoproteiner) i syfte att I) studera insektcellers förmåga att bilda olika 
sockerstrukturer på proteiner; II) skapa starkt bindande antigen till anti-socker 
antikroppar; III och IV) skapa starkt bindande sockerreceptorer till Shigaliknande 
toxiner och fågelinfluensa hemagglutinin. ”P-selectin glycoprotein ligand-1” (PSGL-1) 
är ett kraftigt sockerbeklätt (O-glykosylerat) glykoprotein. Genetisk ligering av cDNA 
kodande för PSGL-1 och Fc delen av musens IgG2b bildar proteinet PSGL-1/mIgG2b. I 
delarbete I) undersöktes vilka O-glykaner som återfinns på PSGL-1/mIgG2b producerat 
i insektcellerna Sf9 (Spodoptera frugiperda) och Hi-5 (Trichoplusia ni). Dessa cellinjer 
används idag i stor utsträckning för produktion av proteiner till forskning och vacciner. 
Analys av O-glykaner frisatta från PSGL-1/mIgG2b visade att insektcellerna åstadkom 
en mer omfattande och komplex O-glykosyleringen än vad som tidigare rapporterats 
vilket kan begränsa deras användning för produktion av proteinläkemedel. 
Glykosyleringen av PSGL-1/mIgG2b kan anpassas genom att producera proteinet i 
genetiskt modifierade cellinjer. Genom att sätta in gener som kodar för PSGL-1/mIgG2b 
tillsammans med glykosyleringsenzymer, kan skräddarsydd glykosylering uppnås. I 
delarbete II) användes genetiskt modifierade Chinese Hamster Ovary (CHO) celler för 
att producera PSGL-1/mIgG2b bärandes blodgrupp A och B på olika (typ 1, 2 och 3) 
sockerkedjor. De multivalenta glykoproteinerna kunde binda upp kedjespecifika anti-A 
antikroppar. Ett möjligt framtida användningsområde för dessa glykoproteiner är 
immunoadsorptionskolonner. Sådana används idag för att ta bort anti-A och anti-B 
antikroppar i samband med organtransplantation över blodgruppsgränserna. I delarbete 
III) och IV) producerades PSGL-1/mIgG2b i olika genmodifierade CHO cellinjer i syfte 
att skapa multivalenta sockerstrukturer som liknar de receptorer som Shiga toxin 1 och 
2 (Stx1 och -2) och fågelinfluensavirusets hemagglutinin (H5) binder till på cellytan. 
Bindningsanalyser med s.k. ”surface plasmon resonance” (Biacore) visade att PSGL-
1/mIgG2b som bar på sockerstrukturen P1 (Galα4Galβ4GlcNAc) band starkt till Stx1 
och Stx2 medan PSGL-1/mIgG2b som bar på Siaα2,3Gal på olika sockerkedjor band 
starkt till fågelinfluensahemagglutininet H5. Det återstår att se om dessa PSGL-
1/mIgG2b glykoproteiner kan hämma toxin- och virusbindning till cellytan. 
Sammanfattningsvis, multivalent presentation av specifika socker på PSGL-1/mIgG2b 
gör att detta glykoprotein kan binda med biologisk relevant styrka till många 
bindningspartners. Detta gör PSGL-1/mIgG2b till ett kraftfullt verktyg med många 
framtida potentiella terapeutiska och diagnostiska användningsområden.  
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Abbreviations	  
 
Asn Aspargine 
BEVS Baculovirus expression vector system 
Blood group A GalNAcα1,3(Fucα1,2)Gal 
Blood group B Galα1,3(Fucα1,2)Gal 
Blood group H Fucα1,2Gal 
CHO Chinese Hamster Ovary cells 
Core 3 enzyme, C3 β1,3-N-acetylglucosaminyltransferase-6 
dHex Deoxyhexose 
DMB 1,2-diamino-4,5-methylenedioxybenzene 
ELISA Enzyme-linked immuno sorbent assay 
ER Endoplasmic reticulum 
ESI Electrospray ionization 
FAB Fast atom bombardment 
Fuc Fucose 
FUT1, H α1,2-fucosyltransferase-1 
FUT2, Se α1,2-fucosyltransferase-2 
GAG Glycosaminoglycan 
Gal Galactose 
GalA Galacturonic acid 
GalN Galactosamine 
GalNAc N-acetylgalactosamine 
GalNAcT α1,3-N-acetylgalactosyltransferase 
GalT α1,3-galactosyltransferase 
GalT5 β1,3-galactosyltransferase-5 
Gb3 Globotriaosylceramide 
GBPs Glycan-binding proteins 
Glc Glucose 
GlcA Glucuronic acid 
GlcN Glucosamine 
GlcNAc N-acetylglucosamine 
HA Hemagglutinin 
HEK Human embryonic kidney cells 
Hex Hexose 
HexA Hexuronic acid 
HexNAc N-acetylhexosamine 
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HPAEC-PAD High-performance anion-exchange chromatography with pulsed 
amperometric detection 
HPAIV Highly pathogenic avian influenza viruses 
HPLC High-performance liquid chromatography 
HUS Hemolytic uremic syndrome 
IA Immunoadsorption 
IdoA Iduronic acid 
LacdiNAc N, N’-diacetyllactosamine 
LacNAc N-acetyllactoseamine 
LC Liquid chromatography 
M1 Matrix protein 1 
M2 Matrix protein 2 
MALDI Matrix-assisted laser-desorption ionization 
Man Mannose 
MS Mass spectrometry 
NA Neuraminidase 
Neu5Ac N-acetylneuraminic acid 
Neu5Gc N-glycolylneuraminic acid 
NMR Nuclear magnetic resonance 
NP Nucleoprotein 
NS1 nonstructural protein 1 
NS2 nonstructural protein 1 
P1 Galα1,4Galβ1,4GlcNAc 
PAA Poly(acrylic acid)amide 
PB1 Polymerase basic 1 
PB2 Polymerase basic 2 
PC Phosphocholine 
Pk Galα1,4Galβ1,4Glc 
ppGalNAcT UDP-GalNAc-polypeptide-N-acetylgalactosaminyltransferase 
PSGL-1/mIgG2b P-selectin glycoprotein ligand-1/mouse IgG2b 
RP Reverse-phase 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser Serine 
Sia Sialic acid 
SPR Surface plasmon resonance 
STEC Shiga toxin-producing Escherichia coli 
Stx Shiga toxin 
Stx1 Shiga toxin 1 
Stx2 Shiga toxin 2 
Thr Threonine 
 12 
TOF Time-of-flight 
Type 1 Galβ1,3GlcNAc 
Type 2 Galβ1,4GlcNAc 
Type 3 Galβ1,3GalNAcα 
β6GlcNAcT-I, C2 Core 2 β1-6 N-acetylglucosaminyltransferase-1 
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1 General	  introduction	  to	  the	  field	  of	  glycobiology	  
Carbohydrates are one of the building blocks of life. Together with nucleic acids, 
proteins and lipids they are key components of all living organisms. Carbohydrates 
serve as building blocks, energy source and carrier of information. The field of 
glycobiology studies the structure, biosynthesis, biology, and evolution of 
oligosaccharides (glycans) in biological systems (Varki and Sharon, 2009).  
Carbohydrates are the most common post-translational modification of proteins and 
contribute to expanding the complexity of the proteome beyond what is encoded in the 
genome. Carbohydrates have important roles in all stages of life including 
development, growth and maintaining a multicellular homeostasis. Carbohydrates are 
found on the cell surface and are involved in interaction with the surroundings 
(extracellular matrix), other cells (including self and non-self) and microbes (bacteria 
and virus). In addition, dynamic glycosylation of proteins are important for intracellular 
signaling. The following sections will give a brief introduction to those parts of 
glycobiology that are relevant for the presented papers in this thesis.   
	  
1.1 Carbohydrates	  as	  carriers	  of	  information	  
Carbohydrates have been called “the third alphabet of life” after nucleic acids and 
amino acids because they share several features with these molecules (Rüdiger and 
Gabius, 2009, Gabius, 2000). While the genetic code is composed of four-letter 
combinations, the sugar code is composed of carbohydrate monosaccharides that 
represent the “letters” of the alphabet and may be joined together in different 
oligosaccharides (glycans) or polysaccharides, “words” or “sentences”.  The 
carbohydrate alphabet may actually carry more information than the nucleic acids and 
amino acids because the structure of carbohydrates is not only determined by the 
sequence of the monosaccharides but also dependent on the linkage between each 
monosaccharide. The linkage may vary in position and anomeric position. Further, the 
sugar ring size may also vary (five- or six-carbon ring). The carbohydrate sequence 
may be branched, something that is not observed in nucleic acids or proteins.  Even 
though not all theoretical combinations of these structural differences are observed in 
nature (that would be an astronomical number), a combination of sequence, linkage 
position and branching are often needed for specific biological recognition by for 
example lectins.  The glycan structures are not template derived; instead the structures 
are dynamic in space and time and dictated by the activity of enzymes in the ER and 
Golgi (see separate sections).   
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1.2 Protein	  glycosylation	  
Several forms of protein glycosylation are found in nature. Glycans are commonly 
attached to proteins via the amino acids asparagine and serine or threonine. Attachment 
to asparagine is mediated via the NH2 group of the amino acid, and thus referred to as 
N-linked glycosylation. In an analogous manner O-linked glycosylation refers to glycan 
attachment to the OH group found in serine and threonine. The biosynthesis of N-
linked and O-linked glycosylation is described in separate sections below. Both forms 
of glycosylation may consist of long and complex chains that may carry additional 
modifications such as sulfate or phosphocholine (paper I). The single O-GlcNAc 
glycosylation that competes with protein phosphorylation is involved in intracellular 
(cytosol and nucleus) signal transduction (Hart et al., 2011). O-Fuc and O-Glc 
glycosylation have been demonstrated to be important in development (Stanley and 
Okajima, 2010). The large carbohydrate polymers of proteoglycans are attached to the 
protein core with O-linked xylose (Couchman and Pataki, 2012) and O-linked mannose 
is quite prevalent in the brain (Stalnaker et al., 2011). O-linked mannose is also found 
on α-dystroglycan that is part of the dystrophin complex that connects the cytoskeleton 
and the extracellular matrix. The O-Man glycosylation is pivotal for the linkage of α-
dystroglycan to laminin found in the extracellular matrix, the molecular basis for the 
contraction of muscles (Stalnaker et al., 2011). Mutations in these glycoproteins are 
therefore associated with muscular diseases (Stalnaker et al., 2011, Hewitt, 2009).  
 
1.2.1 N-­‐glycosylation	  
All N-glycans share a common core sequence, Manα1–6(Manα1–3)Manβ1–
4GlcNAcβ1–4GlcNAcβ1-Asn-X-Ser/Thr (X is any amino acid except proline) and are 
classified in three groups; high mannose (oligomannose), complex and hybrid (Figure 
1B-D). High mannose has only mannose attached to the core, while complex type N-
glycans have extensions (antennae) initiated with GlcNAc residues attached to the core. 
Hybrid structures have both mannose and antennae attached to the core (Figure 1).  
The addition of N-linked glycans to proteins is observed in all eukaryotic cells.  
 
1.2.1.1 N-­‐glycan	  synthesis	  
The N-glycan precursor is synthesized in the endoplasmic reticulum (ER) and consist 
of Glc3Man9GlcNAc2 linked to the dolichol-P lipid (Dol-P) (Figure 1A). The precursor 
is conserved in all eukaryotic cells while the final trimming of the glycans differ 
considerably between plants, yeast, insects and mammals (Betenbaugh et al., 2004). 
The whole glycan precursor is transferred en bloc from the Dol-P lipid carrier to the 
polypeptide chain of the protein that is being synthesized and translocated through the 
ER membrane (Helenius and Aebi, 2004).  The final structures found on mature 
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glycoproteins are then formed by the action of a large set of glycosyltransferases and 
glycosidases in the ER and Golgi. 
 
 
 
 
 
 
Figure 1 Examples of N-glycan types found in mammals (A-D) and insects (A and E-F). 
 
1.2.1.2 Insect	  N-­‐glycosylation	  
Insect and human N-glycosylation are different in several ways. N-glycans of insect 
cells are mostly of the high-mannose or paucimannose type with or without core 
α1,3/6-fucosylation, although low amounts of hybrid- and complex types have been 
reported (Aoki et al., 2007, North et al., 2006, Ten Hagen et al., 2009, Shi and Jarvis, 
2007, Ogonah et al., 1996, Hsu et al., 1997). The typical truncated paucimannosidic 
structure and a complex type N-glycan found in Drosophila melanogaster embryos are 
shown in Figure 1 E and F. Very low amounts of terminal sialic acid suggest a limited 
Asn
Asn
Asn
P-P-DolA) Precursor structure
B) High mannose
C) Complex
D) Hybrid
E) Insect Paucimannose
F) Insect complex
Asn
Asn
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and specialized expression pattern of this monosaccharide in Drosophila (Aoki et al., 
2007). The N- and O-glycosylation of insect cells is described in more detail in the 
Results and Discussion section.  
 
1.2.2 O-­‐glycosylation	  
The most common form of O-linked glycosylation of proteins is initiated with the 
addition of GalNAc to serine or threonine in the ER/Golgi. This is also called mucin-
type glycosylation due to the prevalence of O-GalNAc glycosylation in these proteins 
(mucins, see separate section). Different O-linked inner chain saccharide sequences, 
the “cores”, have been designated different numbers and are listed in Table 1. The cores 
may be further elongated with the terminal structures listed in Table 2.  
 
 
  
Table 1 The O-glycan core structures found in mammals 
 
1.2.2.1 O-­‐glycan	  synthesis	  
In contrast to N-glycan synthesis, the O-glycosylation initiation is achieved by the 
addition of a nucleotide monosaccharide rather than the en bloc transfer of a large 
precursor carbohydrate (Hang and Bertozzi, 2005). The first transfer of GalNAc to the 
polypeptide chain is catalyzed by an UDP-GalNAc-polypeptide-N-
acetylgalactosaminyltransferase (ppGalNAcTs) and takes place in the Golgi. A large 
family of ppGalNAcTs exists which may be explained by the fact that the ppGalNAcTs 
prefer different protein substrates and may be expressed differently in time and space 
(development and tissue tropism) (Hang and Bertozzi, 2005).  No precise amino acid 
consensus sequence has been determined for the acceptor site of O-glycosylation, 
although proline amino acids near the Ser/Thr acceptor site are favorable. The synthesis 
of O-glycan core structures 1 to 4 is shown in Figure 2.  
 
 
Determinant Structure
Tn antigen GalNAcαSer/Thr
Core 1 or T antigen Galβ1-3GalNAcαSer/Thr
Sialyl-Tn antigen Siaα2-6GalNAcαSer/Thr
Core 2 Galβ1-3(GlcNAcβ1-6)GalNAcαSer/Thr
Core 3 GlcNAcβ1-3GalNAcαSer/Thr
Core 4 GlcNAcβ1-3(GlcNAcβ1-6)GalNAcαSer/Thr
Core 5 GalNAcα1-3GalNAcαSer/Thr
Core 6 GlcNAcβ1-6GalNAcαSer/Thr
Core 7 GalNAcα1-6GalNAcαSer/Thr
Core 8 Galα1-3GalNAcαSer/Thr
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Figure 2 Synthesis of O-glycan core structures 1 to 4.  
 
 
 
 
 
 
Table 2 Common terminal carbohydrate determinants that may be found on N-glycans, O-glycans or 
glycolipids 
 
 
 
Ser/Thr
ppGalNAcTs
G3GalT
G3GlcNAcT
G6GlcNAcT
G6GlcNAcT
Ser/Thr
Ser/ThrSer/Thr
Ser/Thr Ser/Thr
Core 2 Core 1
Core 3Core 4
Determinant Structure
Blood groups O, H Fucα1-2Gal-
Blood group A GalNAcα1-3(Fucα1-2)Gal-
Blood group B Galα1-3(Fucα1-2)Gal-
Linear B Galα1-3Gal-
Blood group i Galβ1-4GlcNAcβ1-3Gal-
Blood group I Galβ1-4GlcNAcβ1-6(Galβ1-4GlcNAcβ1-3)Gal-
Blood group Sd(a), Cad GalNAcβ1-4(Siaα2-3)Gal-
Blood group Lewisa Galβ1-3(Fucα1-4)GlcNAc-
Blood group Lewisx Galβ1-4(Fucα1-3)GlcNAc-
Blood group sialyl-Lewisx Siaα2-3Galβ1-4(Fucα1-3)GlcNAc-
Blood group Lewisy Fucα1-2Galβ1-4(Fucα1-3)GlcNAc-
type 1 chain, neo-N-acetyllactosamine Galβ1,3GalNAc-
type 2 chain, N-acetyllactosamine (LacNAc) Galβ1,4GlcNAc-
type 3 chain Galβ1,3GalNAcα
type 4 chain Galβ1,3GalNAcβ
type 6 chain Galβ4Glc
LacdiNAc GalNAcβ1–4GlcNAc-
Chitobiose GlcNAcβ1–4GlcNAc-
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1.3 Function	  of	  O-­‐GalNAc,	  mucin-­‐type	  glycosylation	  
O-glycosylation serves many functions in biology and there is only room to mention a 
few areas of particular importance in this section. O-GalNAc glycosylation of proteins 
contributes to protein structure and stability and is involved in recognition (protein-
carbohydrate binding). The extended structure of mucins and mucin-type proteins is 
highly dependent on dense glycosylation and is described in further detail in a separate 
section below. Highly O-GalNAc substituted proteins are also more resistant to 
proteolytic cleavage and are more heat-stable. Recognition associated with O-GalNAc 
includes cell growth and proliferation, glycoprotein clearance, glycoprotein trafficking, 
immunological recognition and signaling pathways (Tian and Ten Hagen, 2009, Patsos 
and Corfield, 2009b).  
 
1.4 The	  mucosal	  barrier	  
Mucus secretions are part of the protective mucosa barrier of the auditory, 
gastrointestinal, respiratory, and the urogenital systems as well as the conjunctiva of the 
eyes (Perez-Vilar and Mabolo, 2007). The physical protection of the mucus membranes 
consists of the mucosal epithelium, its lamina propria and glycocalyx and secreted 
mucins (Patsos and Corfield, 2009a). The glycocalyx consist of membrane-associated 
glycoproteins, proteoglycans and glycolipids that are continuously renewed in order to 
maintain a defensive barrier (Moran et al., 2011). A highly hydrated mucus gel is 
covering the glycocalyx that consist mainly of large secreted glycoproteins, mucins. 
The mucins may be both membrane bound and secreted, where the latter form is 
disulfide-linked to form oligomers that may be as large as several million Dalton 
(Perez-Vilar and Mabolo, 2007). The name “mucin” was first used by Nicolas 
Theodore de Saussure 1835 when he described substances derived from mucus 
(Gottschalk, 1960). Eichwald and Hammarsten later showed that mucins consist of 
highly glycosylated proteins (Montreuil and Vliegenthart, 1995). The composition of 
the glycocalyx and mucus gel is dependent on the location and the requirements of the 
anatomical location (Ito, 1969, Perez-Vilar and Mabolo, 2007, Patsos and Corfield, 
2009a). The mucus gel serves as a physical barrier that can trap particles but the highly 
glycosylated mucins may also, via their carbohydrate substitutions, specifically bind to 
bacteria and viruses (Patsos and Corfield, 2009a).  Many bacteria and virus use 
carbohydrate receptors at the epithelial cell surface for attachment or uptake into the 
cells (Olofsson and Bergstrom, 2005, Moran et al., 2011).  In addition, the mucus 
contains a range of anti-microbial proteins such as antibodies and host defense peptides 
including defensins, protegrins, collectins, cathlecidins, lysosymes and histatins 
(Kagnoff and Eckmann, 1997, Lu et al., 2002, Raj and Dentino, 2002).  
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1.5 Co-­‐evolution	  of	  host	  and	  pathogens	  
It has been suggested that rapid evolution is shaping the glycosylation of the mucins in 
order to present carbohydrate decoy receptors that will trap microorganisms or mask 
microbial binding sites by capping with additional terminal carbohydrates. Likewise, 
strong selection pressure forces the microbes to evolve quickly in order to remain 
infectious. This has been proposed to be an example of an evolutionary arms race, 
where host and pathogen need to constantly evolve in order to avoid extinction (Varki 
et al., 2009c).  
 
1.6 Mucins	  and	  mucin-­‐type	  proteins	  
Mucins have the O-glycosylation sites (Ser/Thr) clustered together in mucin-domains 
that are found in variable number tandem repeats (VNTR) up to 10-100 times in the 
polypeptide chain (Hang and Bertozzi, 2005). This results in glycoproteins where the 
carbohydrates constitute more than half of the total weight. The tandem repeats are also 
rich in proline (Moniaux et al., 2001). Mucins have been proposed to have an extended 
structure as indicated by several studies (McMaster et al., 1999, Shogren et al., 1989, 
Gerken et al., 1989, Bansil et al., 1995). Many glycoprotein carry the tandem-repeats 
found in mucins and have thus been termed mucin-type or mucin-like proteins, 
although they may not be genetically related to proper mucins.  Studies on the mucin-
like protein CD43 (leokosialin, sialophorin) have shown that GalNAcα  but not 
GalNAcβ contribute to the elongated structure of this glycoprotein (Coltart et al., 2002, 
Live et al., 1999, Live et al., 1996). Another mucin-type protein is P-selectin 
glycoprotein ligand-1 (PSGL-1). In this thesis we have studied the PSGL-1 fused to the 
Fc part of mouse IgG2b to form the PSGL-1/mIgG2b fusion protein (Figure 10). The 
PSGL-1 /mIgG2b is produced as a dimer that carry 32 tandem repeats and have 6 
potential N- and 106 potential O-glycosylation sites (Cummings, 1999, Liu et al., 1997, 
Sako et al., 1993). The large size and the elongated shape of the protein make it suitable 
for interaction with other proteins.  In this thesis PSGL-1/mIgG2b was used as a tool to 
study O-glycosylation (paper I) and as a multivalent carrier of specific carbohydrate 
ligands in paper II-IV.  
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2 Protein-­‐carbohydrate	  interactions	  
 
2.1 Lectins	  
Lectins are ubiquitous glycan-binding proteins (GBPs) found in all living organisms. 
Particularly plant lectins bind with high specificity to specific carbohydrate moieties. 
This feature has been extensively used for the analysis and purification of glycans. 
Since the lectins are so widespread the functions of lectins are also varied (Varki et al., 
2009b). Microbial lectins include attachment factors and toxins, such as influenza 
hemagglutinin and Shiga toxins (Holgersson et al., 2009). These lectins are described in 
further detail in 6.4.1 and 7.3 and are the targets of novel carbohydrate-based inhibitors 
described in paper III and IV. The first mammalian lectin discovered was the 
asialoglycoprotein receptor, which is involved in the clearance of glycoproteins in the 
circulation. This is explained in further detail in section 5.4. Lectins are important in the 
innate immune system where C-type lectins and Siglecs are examples of pattern-
recognition receptors (PRRs) that may have the capacity to regulate innate and adaptive 
immunity (Robinson et al., 2006).  
 
2.2 The	  multivalency	  effect	  of	  protein	  carbohydrate	  interactions	  
Multivalency is a universal principle in nature to achieve strong but reversible binding 
and is important in recognition, adhesion and signaling processes (Fasting et al., 2012). 
Although an individual carbohydrate-protein interaction may be weak, multiplying the 
interaction in a multivalent or polyvalent fashion can radically strengthen the bond 
(Fasting et al., 2012). This type of interaction has been compared to the burr and Velcro 
binding that relies on the combined strength of multiple tiny hooks that entangle with 
loops to form a strong bond. The theoretical models of multivalency and its role in 
biological systems have been extensively reviewed (Mammen et al., 1998) (Fasting et 
al., 2012). A few examples of multivalent interactions mentioned by Mammen et al are 
viral (influenza) and bacterial (fimbriae of E. coli) adhesion to host cell surface, cell-
cell adhesion (neutrophil binding to endothelial cells), binding of cells to polyvalent 
molecules (Fc receptor binding to multiple antibodies recognizing repetitive antigen on 
the surface of a bacterium) and interaction between polyvalent molecules (transcription 
factors binding to DNA sites) (Mammen et al., 1998).  Additional abundant examples 
are given within the review (Mammen et al., 1998).  
The strengthening of a multivalent bond (avidity) compared to a monovalent bond is 
mostly related to the decrease in the dissociation koff value (kd), instead of increase in 
association kon value (ka). This may be explained by the increase in re-binding. If one 
bond is dissociated the remaining bonds keep the unbound ligand and receptor in close 
proximity which facilitates re-binding. Multivalent interactions may or may not be 
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positively cooperative. An example of positively cooperative (synergistic) binding is 
the binding of O2 molecules to hemoglobin where each additional binding becomes 
more favorable as the binding sites becomes occupied (Mammen et al., 1998). It should 
be noted that multivalency is not always associated with cooperative binding (Fasting et 
al., 2012). Even a non-cooperative (additive) or negatively cooperative (interfering) 
multivalent binding may confer stronger and more specific binding compared to 
monovalent binding (Fasting et al., 2012).  
 
2.3 Chemical	  and	  biological	  approaches	  to	  achieve	  multivalency	  
Polyvalent presentation of ligands has been achieved in several ways, for example 
through the use of polyacrylamide polymers (PAA), dendrimers, neoglycoconjugates, 
nanoparticles, liposomes and glycoproteins (Mammen et al., 1998) (Chabre and Roy, 
2009) (Fasting et al., 2012) (Gabius, 2000). Chemically synthesized multivalent 
molecules have several advantages in that they can be made more homogenous than 
glycoproteins and that the shape, spacing and presentation of the ligand may be 
modified in any desirable way. In vivo applications exclude some toxic scaffolds 
however and the synthesis of long carbohydrate chains is still complex (Oscarson, 
2009). Another approach to produce multivalent molecules is to use genetic 
engineering of cell lines to produce multivalent glycoproteins. The production and 
practical application of multivalent glycoproteins with glycan tailored glycosylation has 
previously been a successful strategy in our laboratory. The heavily O-glycosylated P-
selectin glycoprotein ligand-1 genetically fused to the Fc portion of mouse IgG2b 
(PSGL-1/mIgG2b) has been produced in cell lines that have been transfected with 
plasmids encoding glycosyltransferases. This allows the rational glycan design of 
PSGL-1/mIgG2b presenting specific carbohydrates in a multivalent fashion.  
Glycoproteins inherently have larger variability of the carbohydrate epitopes compared 
to chemically synthesized molecules and care must be taken when choosing the 
expression system in order to avoid the production of proteins carrying carbohydrate 
determinants that are immunogenic, mediate binding to endogenous lectins or microbes 
that are not targeted. 
 
2.4 Multivalent	  carbohydrate	  inhibitors	  
Carbohydrates are ubiquitous on all mammalian cell surfaces.  Bacterial and viral 
tropism is therefore often conferred by attachment to species- or tissue-specific 
expression of glycans at the cell surface. In order to achieve strong and specific 
attachment to the cell surface the nature of the binding is often multivalent. It has 
therefore been suggested that potential carbohydrate based inhibitors of bacterial and 
viral attachment must be multivalent. An advantage of a large polyvalent inhibitor is 
the combined effect of competitive inhibition and steric hindrance (Mammen et al., 
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1998). The high concentration of receptor analogues presented by the multivalent 
inhibitor competitively inhibits binding of a virus to the cell surface. In addition virus 
particles that have attached to a large polyvalent (flexible) inhibitor become shielded 
from the cell surface and may also become aggregated with other virus particles that 
have adhered to the polymer. The mechanism has been suggested to be similar to the 
inhibitory effect of natural mucins which bind specifically to certain viruses with the 
carbohydrate moieties and also provide a physical barrier (Mammen et al., 1998). Steric 
hindrance of viral or bacterial attachment to the cell surface does not have to be 
mediated via binding to attachment factors; rather, any factor on the viral or bacterial 
surface may serve as a target for steric inhibition such as influenza NA. In paper III and 
IV the binding of potential carbohydrate-based inhibitors of Shiga-like toxins and avian 
influenza hemagglutinin was investigated.  
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3 Tools	  to	  study	  glycosylation	  
 
3.1 Glycan	  structure	  analysis	  
Carbohydrates are dense in information and therefore several analytical methods are 
needed in order to elucidate all structural details of individual glycans and to determine 
the glycomic profile of glycan mixtures. This section will provide brief information of a 
few commonly used analytical methods used for structural elucidation. Specific 
information regarding some of the methods used in this thesis is found in section 9. 
Methodological considerations.  
 
3.1.1 Western	  blot	  
Specific glycans on glycoproteins can be quickly detected with Western blot where 
separated and blotted glycoproteins are stained with monoclonal antibodies or lectins. 
A wide range of commercially available lectins and antibodies are available that can be 
used to determine the identity and linkage of (mostly terminal) glycans. Western blot is 
also used together with substrate-specific glycosidases. Enzymatic removal of 
carbohydrates is detected as a shift in migration in e.g. SDS-PAGE. 
 
3.1.2 Monosaccharide	  analysis	  
The identification of individual monosaccharides in glycan or glycoprotein samples can 
be determined with several different techniques. The glycan is completely hydrolyzed 
into its monosaccharide constituents, which are identified by their retention times on a 
column compared to known standards. The monosaccharides can be separated by 
HPLC, but may require fluorescent labeling (see below) for detection, or by High 
Performance Anion Exchange Chromatography with Pulsed Amperometric Detection 
(HPAEC-PAD). HPAEC-PAD does not require any labeling of the monosaccharides 
for detection. 
 
3.1.3 Mass	  spectrometry	  
Mass spectrometry (MS) is a sensitive analytical method to detect and identify 
molecules. In mass spectrometry the mass and charge ratio (m/z) of ionized molecules 
are accurately detected. All mass spectrometry instruments contain an ionizer, mass 
analyzer and detector. The ionization of the sample may be achieved in several ways. 
Common types of ionization techniques suitable for the analysis of biomolecules 
include fast atom bombardment (FAB), matrix-assisted laser desorption ionization 
(MALDI) and electrospray ionization (ESI). Different types of mass analyzers include 
sector-, time-of-flight- and quadropole instruments. In this thesis a liquid 
chromatography column separated the glycans prior to electrospray ionization and mass 
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detection.  Different derivatizations of glycans as a way to increase sensitivity and the 
information obtained are described in more detail elsewhere (Zaia, 2004). Mass 
spectrometry generates a wealth of structural information depending on the protocol. 
Glycoprotein analysis gives information on type of glycosylation and site of 
glycosylation, while glycan analysis reveals glycan branching, number and length of 
antennae, composition, substitutions and sequence of individual glycans (Mulloy et al., 
2009). It should be noted that besides glycoproteins and released glycans, MS can be 
used to analyze the structure of glycolipids and GAG-derived glycans (Mulloy et al., 
2009). Linkage position can be determined with partial methylation analysis where the 
fragmentation pattern is compared with known standards. However, this technique does 
not determine if the linkage is of α  or β anomeric configuration.  
 
 
3.1.4 High-­‐performance	  liquid	  chromatography	  
N-glycan structural analysis can be performed with high-throughput analysis using 
high-performance liquid chromatography (HPLC). The N-glycans are released from the 
protein with N-glycosidases that cleaves the bond between Asn and the carbohydrate 
moiety. Derivatized glycans are separated with different columns using HPLC and the 
glycan structures are identified by comparing the elution position with known glycans. 
The structural determination can sometimes be automated by comparing the retention 
times with those of known structures. 
 
3.1.5 Nuclear	  magnetic	  resonance	  
Nuclear magnetic resonance allows the full structural elucidation of unknown samples, 
including composition, linkage and anomericity (α/β). NMR requires a lot of source 
material for a full structural characterization due to the relatively low sensitivity. 
Important though is that the sample is not consumed in the analysis. 
 
3.2 Glycan	  binding	  analysis	  
The interaction between glycan-binding proteins (GBPs) and glycans can be measured 
in several ways (Cummings and Esko, 2009). Binding constants (KD) can be derived 
from near-equilibrium methods such as equilibrium dialysis, equilibrium gel-filtration 
and frontal affinity chromatography (Nakamura-Tsuruta et al., 2006, Bergstrom et al., 
2012). Titration calorimetry can provide more complete thermodynamic information, 
but current instruments require ample material (Dam and Brewer, 2004). Surface 
plasmon resonance (SPR) measures the association and dissociation kinetics between 
an immobilized ligand and its receptor, but may also be used to measure equilibrium 
binding constants (affinity)(Olausson et al., 2011). This technique was used in paper III 
and IV and is explained in more detail in section 9.6. 
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ELISA has been extensively used to determine the KD of the binding of GBPs to 
glycans. Usually this technique requires some sort of coupling of the glycan to biotin 
(for immobilization) or reporter group (for detection). In competition ELISA an 
inhibitory glycan is added to the well and the competition for GBP is measured as a 
function of concentration in order to obtain the IC50 value (and thus KD). In glycan 
arrays the glycans are printed on a surface and GBPs is overlaid and allowed to bind. 
Bound GBP is detected with a fluorescent label that is conjugated either to the GBP 
directly or to an anti-GBP antibody. The binding is typically presented as a histogram 
where binding is measured in fluorescence units. Glycan arrays with hundreds of 
different glycans can give information of the specificity of the GBP but provide no 
binding constants (Paulson et al., 2006).  
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4 The	  ABO	  blood	  group	  system	  
 
4.1 Historical	  background	  
The ABO blood group antigen system was discovered by Karl Lansteiner already 1901 
(Tagarelli et al., 2001). Landsteiner demonstrated that serum factors could agglutinate 
red blood cells from other humans and based on his observations divided humans into 
different blood groups.  Landsteiner was awarded the Nobel prize in 1930 for his 
discovery (Tagarelli et al., 2001). Subsequent experiments have shown that the serum 
factors are antibodies and that the antigens on the red blood cells are glycan epitopes. In 
addition to the ABO system, several additional blood group systems have now been 
discovered (Storry and Olsson, 2009).  The structural and genetic elucidation of the 
ABO antigens was largely revealed by Watkins (Watkins, 1966) and  Kabat (Kabat, 
1956) but the glycosyltransferase genes responsible for the biosynthesis of A and B 
were not cloned until 1990 by Yamamoto et al. (Yamamoto et al., 1990a, Yamamoto et 
al., 1990b).   
 
4.2 Structures	  and	  distribution	  
The distribution of the blood group determinants is cell- and tissue-dependent. The 
expression of the ABO blood group determinants on different precursor type chains 
(type 1, 2, 3 and 4) has been extensively reviewed (Clausen and Hakomori, 1989) 
(Ravn and Dabelsteen, 2000, Holgersson et al., 1992). These studies have mainly been 
performed on extracted glycolipids or immunohistochemical staining of tissues with 
chain type-specific antibodies that do not show if the blood group determinants are 
carried by glycoproteins or glycolipids.  
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Figure 3 ABO (H) blood group determinants on different carbohydrate outer type chains 
 
 
 
H type 1
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B type 2
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Ser/Thr Ser/Thr Ser/Thr
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4.3 The	  medical	  importance	  of	  the	  ABO	  system	  
The ABO blood group antigen system has important medical implications. If blood is 
transfused between individuals of different blood groups, e.g. A to O, circulating IgM 
antibodies would immediately bind to donor red blood cells and trigger complement 
activation and lysis. This is a serious condition that can lead to hypotension, shock, 
renal failure and death (Storry and Olsson, 2009). Blood typing is thus important for 
blood- and serum transfusions. 
 
4.4 Immunoadsorption	  
Prior to transplantation of kidney, heart and liver, blood group compatibility is ensured. 
However, due to the shortage of organs, kidney (and now also other organs) 
transplantation across the ABO barrier has recently been increasingly performed. The 
graft survival rates have been similar to those observed for ABO compatible kidneys 
(Genberg et al., 2008). ABO incompatible transplantation may be improved with 
immunoadsorption (IA) of ABO reactive antibodies using extracorporeal affinity 
columns carrying synthetic ABO determinants (Tyden et al., 2005). The A- and B-
columns carry the trisaccharide determinants [A:  GalNAcα1-3(Fucα1-2)Gal and B: 
Galαl- 3(Fucαl-2)Gal] covalently linked via a six-hydrocarbon spacer to Sepharose 
beads. Although, the columns were highly biocompatible and successfully reduced the 
anti-A/B titers (Rydberg et al., 2005), the trisaccharide blood group determinants may 
not remove all A/B reactive antibodies. Determining the fine antigen specificity of the 
anti-A/B antibodies before and after transplantation requires blood group determinants 
on several core chains (Lindberg et al., 2013).  In paper II cell lines were engineered in 
order to produce glycoproteins carrying the blood group determinants on type 1, 2 and 
3 outer core chains. Currently, the use of the glycoproteins carrying the blood group 
determinants in analytical (fine specificity of anti-A/B titers pre- and post-
transplantations) and therapeutic use (immunoadsorption of anti-A/B antibodies) is 
being explored.  
 
4.5 ABO	  synthesis	  
The blood group antigens may be found on several terminal chains, as demonstrated in 
Figure 3. The synthesis of the blood group determinants is described in detail in paper 
II.  
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5 Recombinant	  therapeutic	  proteins	  
 
5.1 Increasing	  economical	  and	  medical	  importance	  	  
Recombinant proteins such as hormones, growth factors, cytokines, enzymes, vaccine 
components and antibodies are examples of important licensed therapeutic proteins that 
account for an increasing share of the revenues in the pharmaceutical industry 
(Fernandez and Muyldermans, 2011). More than two hundred (of which ~100 are 
unmodified) therapeutic proteins have been approved for clinical use in the European 
Union and the USA. The total sales 2010 was 108 billion US$, with monoclonal 
antibodies (mAbs) accounting for half of the sales (Dimitrov, 2012).  
 
5.2 Glycosylation	  affects	  protein	  function	  and	  stability	  
Glycoproteins account for more than two thirds of the available therapeutic proteins on 
the market today (Li and d'Anjou, 2009). The biological function of glycoproteins is 
usually defined by the polypeptide chain, while the carbohydrate moiety influences 
stability, solubility, bioavailability, in vivo activity, pharmacokinetics, and 
immunogenicity (Li and d'Anjou, 2009). Mammalian cell lines (including human) are 
frequently used for the production of therapeutic proteins, even though non-human 
glycosylation may occur (Li and d'Anjou, 2009) (table 3).  In contrast to most small 
molecule drugs, therapeutic proteins are heterogeneous. It has been realized that a vast 
number of variants may exist that differ with regard to a wide range of structural 
features including glycosylation, disulfide bond formation, modifications of amino 
acids, conformation and aggregation (Liu et al., 2008).  The acceptable variability must 
be evaluated individually for each therapeutic protein with pre-clinical and clinical 
studies that demonstrates the importance of the glycosylation with regard to 
pharmacokinetics, bioavailability, clearance and potency (Li and d'Anjou, 2009).  It 
should be noted that the glycosylation pattern of endogenous human proteins may be 
dynamic and that it is not always clear which “native” glycosylation that the 
recombinant therapeutic proteins should mimic (Hossler et al., 2009).  
 
5.3 Glycosylation	  dictates	  the	  effector	  function	  of	  IgG	  antibodies	  
The carbohydrate moiety of therapeutic glycoproteins that are administrated in the 
circulation may bind to several receptors that influence their half-life and effector 
function. A prime example is antibodies, the effector function of which is highly 
dependent on the fine glycosylation of the Fc portion. Currently, all licensed antibodies 
are of the IgG class (Jefferis, 2009). While the Fab domains of antibodies mediate the 
antigen binding, the Fc portion interacts with receptors that activate the effector 
functions. The receptors include the Fcγ receptors (FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, 
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FcγRIIIa, FcγRIIIb), the C1q component of the complement system and neonatal Fc 
receptor (FcRn) (Jefferis, 2009). Fc receptors are present on a wide range of leukocytes 
and the IgG binding can activate or inhibit inflammatory responses by the interaction of 
different IgG subclasses and glycosylation variants with specific Fc receptors 
(Nimmerjahn and Ravetch, 2005). The effector function may be fine-tuned with 
specific glycosylation of both IgG and the Fc receptor (Ferrara et al., 2006). Non-
fucosylated Fc portion of IgG1 results in maximal Antibody-Dependent Cell-Mediated 
Cytotoxicity (ADCC) effector function, while non-glycosylated Fc of IgG2 have 
minimal effector function (Jefferis, 2007). Binding to C1q mediates activation of the 
complement cascade and neonatal Fc receptor controls the half-life of IgG in 
circulation and has a role in placental transport from mother to fetus (Basta, 2008, 
Jefferis, 2009).  
 
5.4 Sialylation	  influences	  the	  half-­‐life	  of	  glycoproteins	  in	  the	  circulation	  
The half-life in circulation of several therapeutic proteins is highly dependent on the 
sialylation. The asialoglycoprotein receptor (ASGP-R) is abundantly expressed on the 
cell surface of hepatocytes, and was initially identified and characterized by its ability 
to rapidly remove glycoproteins carrying terminal Gal or GalNAc from the circulation 
(Ashwell and Harford, 1982, Morell et al., 1971).  
 
5.5 Specific	  glycosylation	  may	  improve	  future	  drugs	  
The half-life and effector function of therapeutic proteins is largely controlled by the 
specific glycosylation of the protein and the lectins to which they bind. Detailed studies 
of how antibodies exert their function have revealed a dynamic and complex system 
that regulates the effector function of antibodies. Almost thirty years ago it was noted 
that different glycoforms of antibodies were observed during different stages of 
rheumatoid arthritis (Parekh et al., 1985). We now know that the increased levels of G0 
glycoforms (lacks terminal sialic acid and galactose) observed during disease are pro-
inflammatory. The understanding of how glycosylation affects the function of 
therapeutic antibodies will hopefully in the near future lead to more efficient drugs with 
fewer side-effects.  
 
 
5.6 Cell	  lines	  used	  for	  production	  of	  therapeutic	  proteins	  
Therapeutic proteins are currently produced in a range of cell lines, that each has their 
strength and weaknesses. Most of the current licensed therapeutic glycoproteins are 
produced in Chinese Hamster Ovary cells (CHO), mouse myeloma cells (NS0, SP/0) 
and hybridomas (Durocher and Butler, 2009) (table 3)  
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Table 3 Summary of the common expression systems and their suitability for the production of 
therapeutic proteins 
 
5.6.1 Chinese	  Hamster	  Ovary	  cells	  (CHO)	  
CHO cells are the most widely used cells today and will continue to be so in the near 
future due to a history of regulatory approvals of licensed recombinant drugs and the 
continuous development of productivity of the cells. CHO cells have an active α2,3 
sialyltransferase and α1,6 fucoylstransferase (N-linked core fucosylation). Genetic 
engineering is needed in order to produce glycoproteins with terminal α2,6 sialylation 
or α1,2/3/4 linked fucose (blood group determinants), respectively (Durocher and 
Butler, 2009, Xu et al., 2011). Low amounts of Neu5Gc and terminal Galα1,3Gal 
epitopes have been reported on proteins produced in CHO cells (Bosques et al., 2011). 
This is potentially problematic since these epitopes are not found in humans and are 
known to elicit immune responses (Chou et al., 1998, Ghaderi et al., 2010, Macher and 
Galili, 2008). However, the levels do seem to be low or non-detectable in comparison 
to murine cell lines (Xu et al., 2011, Bosques et al., 2011). The O-glycosylation 
capacity of CHO cells is limited unless genetically engineered. We have analyzed the 
heavily O-glycosylated mucin-like PSGL-1/mIgG2b fusion protein produced in CHO 
cells in our laboratory and the main O-glycans are core 1 with- and without sialic acid 
(paper IV). However, in paper II we show that complex carbohydrates, such as blood 
group determinants may be produced if the CHO cells are transfected with cDNAs 
encoding the required glycosyltransferases.  
 
Expression system Products Positives Negatives 
Mammalian 
hamster: Chinese hamster ovary cells 
(CHO), BHK21 mouse myeloma cells: 
(NS0, SP2/0) 
human cells: HT1080m HEK-293 
novel human cell lines: PER.C6, 
HKB11 
 antibodies 
 biologically active large 
recombinant proteins with 
multiple PTMs, (Factor VIII) 
 well characterized 
 can produce large, complex 
proteins requiring post-
translational modifications 
(PTMs) 
 human-like glycosylation 
 approval for human 
therapy from regulatory 
authorities  
 mutant cell lines available 
 safety (virus) 
 costs 
 non-human cell lines may produce 
Neu5Gc and GalF1,3Gal 
(hypersensitivity reactions) and may lack 
F2,6 sialyltransferase, F1-3/4 
fucosyltransferase and  
N-acetylglucosamine transferase III.  
Insect, baculo-virus expression 
system, Spodoptera frugiperda: Sf9, 
and Sf21. Trichoplusia ni (Hi-5), 
Bombyx mori, Drosophila frugiperda 
(S2) 
Vaccine antigens (Cervarix, Ph.3 
trials: Provenge, Flublok, 
Chimigen), virus-like particles 
 high expression levels 
 safe production (no human 
pathogen risk) 
 easy (no CO2 needed) 
 High-mannose and paucimannose, 
currently no therapeutic protein – risk of 
adverse reactions  
 low sialylation 
 immunogenic F1,3-fucose 
Yeast: Pichia pastoris, Sacharomyces 
cerevisiae, Hansenula polymorpha 
Vaccine antigens,non-
glycosylated proteins: albumin, 
insulin, growth hormone 
 high yields 
 easy to grow 
 cheap 
 mannose may bind to C-type 
lectins on immune cells 
 Only approved for non-glycosylated 
proteins 
 no Tyrosine O-sulfation 
 N- and O-linked high-mannose is 
immunogenic in humans 
Plants: Lemna minor, carrot cells Edible oral vaccines, interferon 
alpha (Locteron) 
 Cheap 
 safe 
 ~ low yields 
 proteolytic degradation 
 gene silencing 
 no sialylation 
 immunogenic F1,3-fucose and G1,2-
xylose 
Transgenic animals: goat milk, 
chicken eggs,  
Atryn, human anti-thrombin  high fidelity  expensive 
 non-human glycosylation 
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5.6.2 Human	  cell	  lines	  
Production of recombinant therapeutic proteins in human cell lines generally results in 
glycoproteins with more human-like glycosylation that is devoid of immunogenic 
glycans commonly observed in other mammalian cell lines. Examples of human cell 
lines that produce licensed drugs include HEK-293, HT-1080, Namalwa, PerC6 and 
HKB11 (Durocher and Butler, 2009).  
 
5.6.3 Insect	  cell	  lines	  
Recombinant protein production in insect cells is often performed with the baculovirus 
expression vector system (BEVS) that enables rapid production of large amounts of 
proteins (Roldao et al., 2011). Common cell lines include Spodoptera frugiperda 
derived Sf9/Sf21, Trichoplusia ni derived High-five cells, Bombyx mori (silkworm) and 
Mamestra brassicae. In paper I the O-glycosylation capacity of Sf9 and Hi-5 cells was 
investigated. Because the N-glycosylation (see Results and Discussion) and O-
glycosylation (paper I) is significantly different compared to human glycosylation, no 
approved human drugs are currently produced in insect cells. However, vaccine 
components are currently being produced in insect cells and several novel insect cell-
derived vaccines are in clinical trials (Cox, 2012). 
 
5.6.4 Yeast	  
Several non-glycosylated approved therapeutic proteins such as insulin, growth 
hormone and albumin are produced in yeast cells such as Pichia pastoris, 
Saccharomyces cerevisiae and Hansenula polymorpha (Durocher and Butler, 2009). 
Glycoproteins produced in yeast are heavily mannosylated which targets them to 
dendritic cells via C-type mannose-specific lectin receptors which may or may not be 
desirable depending on intended use of the protein (Lam et al., 2007, Dasgupta et al., 
2007, Gustafsson et al., 2011, Ahlen et al., 2012). Yeast cells have been extensively 
genetically engineered in order to produce proteins with human like N- and O-linked 
glycosylation (Hamilton and Gerngross, 2007).   Yeast may thus be an important source 
of therapeutic proteins in the future due to the relative ease of large-scale cultures, high 
protein yields and more homogenous glycosylation (Hamilton and Gerngross, 2007).  
 
5.6.5 Plants	  
Production of therapeutic proteins, “pharming”, is currently performed in several plants 
such as carrot cells and Lemna minor.  Plants could be a suitable source of edible oral 
vaccines but so far the progress has been hampered by low yields (Davoodi-Semiromi 
et al., 2009). At present a few therapeutic proteins are approved for topical use but 
several novel therapeutic proteins are in clinical trials (Karg and Kallio, 2009).  
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5.6.6 Bacteria	  
A few licensed aglycosylated therapeutic proteins are produced in E. coli (Zhu, 2012). 
Although these cells are less commonly used than mammalian cells and are less 
optimized for the production of large proteins, aglycosylated antibodies may sometimes 
be advantageous (Simmons et al., 2002).   
 
5.7 Several	  factors	  affect	  glycosylation	  of	  therapeutic	  proteins	  
The glycosylation of therapeutic glycoproteins does not only depend on the choice of 
cell line. Different culture conditions such as growth rate, temperature, pH, metabolic 
profile and dissolved oxygen, medium and nutrients, serum, glucose- and ammonium 
levels and choice of bioreactor all affect the glycosylation of therapeutic proteins (Zhu, 
2012).  Importantly, there is no expression system that is recommended in general for 
all glycoproteins. A systematic investigation of the vector system, cell line and product 
is needed in order to fully understand the impact of each factor for the final 
glycosylation (Hossler et al., 2009). The desired post-translational modifications dictate 
the choice of production system. The yields obtained of recombinant proteins are 
highly dependent on the optimization of vector design, transfection protocols and 
selection (gene amplification with selection drugs) and screening tools. Optimization 
steps of vectors include a strong promoter, the signal peptide, selected introns, codon 
optimization and chromatin opening elements (Zhu, 2012).    
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6 Influenza	  
 
6.1 Classification	  and	  historical	  background	  
In paper IV the in vitro binding of a potential inhibitor of avian influenza H5 
hemagglutinin was investigated. The following section will give a background on 
influenza type A that has great impact on human health.  Influenza virus belong to the 
family of Orthomyxoviridae and is divided into three types; A, B and C, (Baigent and 
McCauley, 2003, Cheung and Poon, 2007). Influenza A virus is enveloped and has a 
genome that consists of eight negative sense single stranded RNA segments that encode 
ten proteins. Influenza is classified by the two surface antigens it carries in the 
envelope, hemagglutinin (HA) and neuraminidase (NA). Seventeen HA subtypes (H1-
H17) have been identified and ten NA subtypes (N1-N10) (Fouchier et al., 2005) (Sun 
et al., 2013). Although the main reservoir of influenza A is aquatic birds, the virus has a 
broad host tropism and also infects humans and other mammals.  In contrast to the 
widespread infectivity in birds, only three influenza A strains have been fully adapted 
to humans the last century. Mankind largely lacked immunity against these novel virus 
variants that consequently caused worldwide pandemics; H1N1 (1918-1920, “Spanish 
flu”), H2N2 (1957), H3N2 (1968-present), H1N1 (1977-present) and H1N1 (2009) 
(Baigent and McCauley, 2003, Cheung and Poon, 2007).  Although, the 1918, 1977 
and 2009 pandemics were all caused by H1N1 strains, other virulence factors 
contributed to the severe outcome of the 1918 “Spanish flu” pandemic which caused 
more than 40 million deaths worldwide compared to the estimated ~285000 who died 
in the 2009 pandemic (Palese, 2004, Dawood et al., 2012). Occasionally other strains 
such as H5N1, H7N7, H9N2 and recently H7N9 have been isolated from human, 
although these strains display limited spread among humans (Cheung and Poon, 2007, 
Gao et al., 2013). Some of these strains are highly pathogenic, as described below.  
  
6.2 Disease	  
Symptoms of influenza are characteristically high fever, chills, sore throat, headache, 
runny or stuffy nose, weakness, muscle pain and sometimes diarrhea (Gao et al., 2013). 
Although, more severe than a common cold, the disease is usually self-contained. Risk 
groups include children, elderly and individuals with pulmonary or cardiovascular 
complications and immune compromised individuals. Influenza infection is mainly 
spread via inhalation of aerosols but may also infect via the eyes.   People above the 
age of 65 accounts for 90% of all deaths caused by seasonal influenza (Metersky et al., 
2012).    
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6.2.1 Highly	  pathogenic	  avian	  influenza	  viruses	  and	  human	  adaption	  
Highly pathogenic avian influenza viruses (HPAIV), of which H5N1 is a prominent 
example, are of particular interest due to their sporadic outbreaks associated with high 
death rates. Since 2003 HPAIV have been confirmed in 570 individuals with a 60% 
fatal outcome (Kuiken et al., 2012). In comparison, the Spanish flu had maximum death 
rate of 7% (Morens et al., 2010). Fortunately, HPAIV does not yet spread readily 
between humans (Kuiken et al., 2012). The increased pathogenesis associated with 
HPAIV infection is not entirely understood.  Both unique virulence factors of the virus 
and an inappropriate immune response contribute to a “cytokine storm” that induces a 
systemic inflammatory response syndrome that may lead to multi-organ failure and 
death (Tisoncik et al., 2012, Kuiken et al., 2012).  
 
6.3 Life	  cycle	  of	  influenza	  
The infectious cycle of influenza is schematically depicted in Figure 5. In addition the 
figure shows how different anti-viral agents target different stages of influenza 
infection.  
 
6.4 Structure	  of	  influenza	  virus	  
The influenza virus particle has an envelope that is derived from the host cell 
membrane and is acquired in the budding process (Nayak et al., 2004). Three proteins 
are found in the envelope; hemagglutinin (HA), neuraminidase (NA) and matrix protein 
2 (M2). HA bind to the host cell surface receptor sialic acid and in addition mediate 
subsequent fusion of virus and host membranes (Skehel and Wiley, 2000). This protein 
is described in further detail below. NA is an enzyme that hydrolyzes sialic acid, the 
receptor of influenza. NA may have a role in both attachment and release from cells 
(Nayak et al., 2004). M2 is an ion channel protein (function described in Figure 5 
legend). Additional components of influenza virus are shown in Figure 4. 
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Figure 4 Schematic 3D model of an influenza virus particle. The proteins that build up the virus are 
indicated. Source: Wikipedia commons (public domain license).  
 
6.5 Hemagglutinin	  receptor	  specificity	  and	  biological	  role	  of	  HA	  
Hemagglutinin is abundant (~500) in the virus envelope of the influenza particle 
(Stegmann et al., 1987). The name hemagglutinin is derived from the early observation 
that HA can agglutinate red blood cells (Beaumont and Lorenzelli, 1972). HA is found 
as a homotrimer in the envelope of the virus particle where it may bind up to three 
sialic acid moieties. The receptor binding specificity that is conferred by HA has 
important biological consequences. Siaα2,3Gal and Siaα2,6Gal are terminal 
carbohydrate determinants that are ubiquitous on avian and mammalian cell surfaces. 
Different HA molecules have different specificities to Siaα2,3Gal and Siaα2,6Gal 
carbohydrates receptors, respectively. As little as a single amino acid substitution may 
change the specificity towards either of the carbohydrates (Rogers et al., 1983). Human 
adapted influenza binds to Siaα2,6Gal, avian influenza binds to Siaα2,3Gal and swine 
influenza may bind to both receptors (Suzuki et al., 2000, Matrosovich et al., 1997). 
The specificity of HA reflects the distribution of the different sialic acid linkages in the 
different hosts and also contributes to the observed tissue tropism (Suzuki et al., 2000). 
In humans, swine and horse influenza cause respiratory tract infection while in birds the 
infection is enteric. Interestingly, human mucus is rich in Siaα2,3Gal and avian mucus 
has Siaα2,6Gal (Olofsson et al., 2005). However, in the human eye the sialic acid 
linkage of the ocular surface (Siaα2,3Gal) and the mucus (Siaα2,6Gal) is similar to the 
distribution in the intestine of birds. This may explain the reports of human eye 
infections caused by avian strains of influenza (Fouchier et al., 2004). In conclusion, 
the distribution of Siaα2,3Gal and Siaα2,6Gal on different host cell surfaces and the 
mucus layer contributes to the observed host and tissue tropism of avian and human 
influenza. The effect that amino acid substitutions in the receptor binding site has on 
receptor specificity has been extensively studied and is review elsewhere (Skehel and 
Wiley, 2000). 
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The fine receptor specificity of human and avian influenza has been analyzed in vitro. 
In a comprehensive study, duck influenza preferentially bound to 
Siaα2,3Galβ1,3GlcNAc conjugates, while chicken and mammalian influenza bound 
with highest affinity to Siaα2,3Galβ1,4GlcNAc and Siaα2,6Galβ1,4GlcNAc core 
saccharide chains, respectively (Gambaryan et al., 2005). The technique that is used to 
measure the affinity and specificity of HA may influence the obtained results. Glycan 
array and ELISA assays have indicated that the optimal binding partner of highly 
pathogenic H5N1 hemagglutinin is Siaα2,3Galβ1,4(SO3H-)GlcNAcβ (Stevens et al., 
2006) (Gambaryan et al., 2005). In a Biacore assay performed with the same 
recombinant H5 as the glycan array assay, there was no difference observed in affinity 
to Siaα2,3Gal on different inner carbohydrate chains (Suenaga et al., 2012).  
Interestingly, a recent study that used totally different techniques to measure HA 
binding to the cell surface (optical tweezers, atomic force microscopy-based single-
molecule force spectroscopy and molecular dynamics simulations) came to the 
conclusion that human influenza A X-31 bound equally well to cells expressing either 
terminal Siaα2,3 alone or both Siaα2,3 and Siaα2,6 (Sieben et al., 2012). The affinity 
differences between different receptors may thus be lower than expected in vivo 
(Sieben et al., 2012).   
 
6.6 High	  mutation	  rate	  of	  influenza	  	  
Small changes in the virus proteins, often affecting the glycosylation, “drift”, may 
allow the virus to escape from neutralizing antibodies and anti-viral drugs (Wolf et al., 
2006). Strains with novel traits can easily be formed by genetic re-assortment of RNA 
segments in hosts co-infected with two different strains, referred to as genetic “shift” 
(Webster et al., 1992).  
 
6.7 Anti-­‐influenza	  treatments	  
6.7.1 Vaccines	  
A range of strategies to prevent or treat influenza has been attempted, with vaccination 
being the most successful so far. Due to the high mutation rate, “drift”, of human 
influenza the vaccine companies have to make new vaccine formulation each year to 
combat seasonal influenza (Kaiser, 2006). Efforts have been made to make broad-
spectrum vaccines that would give long-lasting immunity (Kaiser, 2006, Gomez 
Lorenzo and Fenton, 2013). Other novel strategies involves DNA vaccination that is 
known to give a stronger cellular immune response and cell-based vaccine production 
systems that are cheaper and faster than egg production (Josefsberg and Buckland, 
2012, Cox, 2012). The shortage of influenza antigen 2009 forced some vaccine 
companies to use higher doses of adjuvant that may have contributed to the rare 
unexpected side effect narcolepsy (Kothare and Wiznitzer, 2013). A major problem 
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with influenza vaccination is that elderly, one of the risk groups of influenza, have 
weaker immune responses to vaccinations (Weinberger and Grubeck-Loebenstein, 
2012).  
 
6.7.2 Antivirals	  
In the course of a pandemic, vaccine supplies may not be sufficient. In this situation 
there is a need for alternative anti-influenza treatments. Indeed, during the 2009 
pandemic governments stock-piled the two most common anti-influenza drugs 
oseltamivir (Tamiflu; Roche/Genentech) and zanamivir (Relenza; GlaxoSmithKline) to 
a cost of US $4 billion (Barik, 2012). A wide range of antiviral treatments of influenza 
has been attempted, targeting different steps of the infectious cycle, summarized in 
Figure 5. Current drugs include the M2 channel inhibitors (adamantanes) and 
neuraminidase inhibitors (Barik, 2012, Lagoja and De Clercq, 2008). Neuraminidase 
inhibitors are examples of drugs invented through rational drug design, and which 
resulted in a small molecule drug binding with high affinity to neuraminidase, 
preventing the hydrolysis of sialic acid receptors. Resistance to NA inhibitors have 
appeared (Moscona, 2005). A recent extensive Cochrane review of neuraminidase 
inhibitors reported a modest 21h reduction of symptoms and no reduction of 
hospitalizations (Jefferson et al., 2012). Several novel NA inhibitors are now in clinical 
trials (Barik, 2012).  Other novel drugs in clinical trials include an RNA polymerase 
inhibitor (purine mimic), and hemagglutinin (inhibitory peptides) and neuraminidase 
(destroys host cell receptors) inhibitors (Barik, 2012, Lagoja and De Clercq, 2008). As 
noted above, the pathogenicity of influenza is often the result of the immune response. 
Anti-inflammatory treatments have therefore been attempted with a number of different 
drugs (Barik, 2012).  
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Figure 5 Illustration of influenza virus infectious cycle and the blocking of the different steps 
with anti-viral agents. Adsorption of virus to the cell surface is mediated by binding of 
multiple HA molecules to Siaα2,3/6Gal- on the cells surface. An inhibitor of influenza 
attachment should be multivalent in order to be effective. In paper IV the binding of a novel 
multivalent avian HA inhibitor was investigated. The inhibitor is based on PSGL-1/mIgG2b 
that present terminal Siaα2,3Gal in multiple copies. After attachment, receptor mediated 
endocytosis leads to viral internalization. The low pH of the endosome induces a HA 
conformational change that fuses viral and endosome membranes. M2 allows proton transfer 
to the interior of the virus particle and release of RNA to the cytoplasm. Adamamtan 
derivatives block this step (M2 inhibitors). RNA replication and transcription in the nucleus 
may be blocked by inosine 5′-monophosphate (IMP)- and RNA polymerase inhibitors. Viral 
mRNA may be targeted by small interfering RNAs (siRNAs). After packaging and budding at 
the cytoplasmic membrane the release may be blocked with neuraminidase inhibitors.    
Currently, only neuraminidase inhibitors and adamantane derivatives are approved for human 
therapy.  Adapted from (De Clercq, 2006, Palese, 2004). 
 
6.7.3 Novel	  multivalent	  carbohydrate	  inhibitors	  
It has been suggested that the influenza virus particle bind with high avidity to the cell 
surface due to the combined strength of many individual HA bonds to sialic acid 
receptors. A potential inhibitor must therefore be multivalent in order to be biologically 
relevant. This has also been shown in several studies (Bovin et al., 2004, Matrosovich 
and Klenk, 2003, Totani et al., 2003, Ogata et al., 2009).  In paper IV we investigate the 
binding strength of a potential inhibitor of avian influenza H5N1 hemagglutinin in a 
Biacore assay.  
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7 Shiga	  toxin	  producing	  bacteria	  
 
7.1 Introduction	  
Shiga toxins are a family of toxins produced by Shigella dysenteriae (Shiga toxin) and 
some strains of Escherichia coli (Shiga-like toxins; Shiga toxin 1 and 2). Shiga toxins 
adhere to the cell surface of host cells and after cellular uptake inhibit protein synthesis 
by targeting the ribosomes leading to cell death. A common complication of Shiga 
toxin-producing E. coli (STEC) infections is hemolytic uremic syndrome (HUS). 
Limited treatment options are available for disease caused by STEC including the HUS. 
In paper III we analyze the binding between Shiga-like toxins and a recombinant 
mucin-like protein that may serve as a potential novel inhibitor of Shiga-like toxins. In 
this section, a brief background of Shiga toxins will be given although the detailed 
intracellular toxic mechanism of action and its use as a tool to study intracellular 
trafficking is beyond the scope of this thesis and can be found elsewhere ((Bergan et al., 
2012) and references within).  
 
7.2 Historical	  background	  
For historical reasons the members of the Shiga toxin family have been given several 
names that are sometimes used interchangeably. The Shiga toxin name is derived from 
the bacterium Shigella dysenteriae. The toxin was first described 1903 (Conradi, 1903, 
Neisser and Shiga, 1903) and was then termed “Neurotoxin” due to its ability to induce 
paralysis and death when injected into rabbits. Later it was discovered that some E. coli 
strains produce similar toxins termed “Verotoxins” and “Shiga-like toxins”. The toxin 
produced in S.  dysenteriae is today referred to as Shiga toxin and the two E. coli-
derived toxins are termed Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2) or Shiga-like 
toxin 1 and 2 (SLT1/SLT2)  (Bergan et al., 2012). Several E. coli strains produce 
variants of the Stx1 and Stx2 (Bergan et al., 2012).  
 
7.3 Structure	  of	  Shiga	  toxins	  
The Shiga toxins belong to the bacterial AB5 toxin family. The AB5 toxin family 
includes additional members such as cholera toxin, heat-labile enterotoxins I and II, 
Campylobacter jejuni enterotoxin and pertussis toxin (Merritt and Hol, 1995). The 
toxins bind to different glycolipid receptors at the cell surface with the B pentamer 
while the A subunit has an enzymatic activity that confer their different toxic effector 
functions. Shiga toxin (Stx) and Shiga toxin 1(Stx1) are almost identical while Shiga 
toxin 2 (Stx2) share less sequence homology (Bergan et al., 2012).  
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Figure 6 Space-fill 3D model of Stx1 B pentamer complexed with the Gb3 analogue 8-
(methoxycarbonyl)-octyl trisaccharide (Pk-MCO), where the Pk terminus is the same as the carbohydrate 
portion of the glycolipid Gb3Cer. Each B subunit binds to three trisaccharides, fifteen in total. The 
terminal Galα1,4 moiety is marked in yellow. Source: Protein Data Bank 
(http://www.rcsb.org/pdb/home/home.do, last accessed April 24 2013), accession number 1BOS (Ling et 
al., 1998). 
 
 
 
7.4 Binding	  
It is believed that the native receptor of Shiga toxins is the glycosphingolipid Gb3Cer 
(globotriaosylceramide). Each B subunit has three binding sites, thus theoretically 
resulting in a total of fifteen binding sites per pentamer. The carbohydrate moiety of 
Gb3Cer is Galα1,4Galβ1,4Glc (also known as the Pk antigen) to which the B pentamer 
binds specifically. Removal of the Gb3Cer receptor protects mice challenged with 
Shiga toxin and cells that lack Gb3Cer are sensitized by incorporation of Gb3Cer in the 
cell membrane (Okuda et al., 2006, Waddell et al., 1990). Gb3Cer is expressed in 
humans on the surface of red blood cells, in the urinary tract, kidney epithelium and 
endothelium, but is also observed in a subset of cells in the intestine, platelets, and in a 
subset of B lymphocytes (Devenica et al., 2011, Engedal et al., 2011). In addition, 
Shiga toxins may bind to Gb3Cer on a subset of cells in the peripheral and central 
nervous system (Ren et al., 1999, Obata et al., 2008). It is not clear why Shiga toxin 
specifically targets the kidneys during HUS when the Gb3Cer receptor is found on a 
range of cells. Shiga toxins are not observed free in circulation, but appear to be bound 
to the surface of polymorphonuclear leukocytes (Brigotti et al., 2011).  Therefore it has 
been proposed that Shiga toxins are delivered to the kidney by the leukocytes. The type 
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of presentation of Gb3Cer on the cell surface of kidney cells may also contribute to the 
binding specificity, see below.  It is also possible that Shiga toxin can bind to other 
receptors on the cells in the kidney. It has been shown in vitro that Stx1 binds well to 
P1 (Galα1,4Galβ1,4GlcNAc) ((Gallegos et al., 2012) and paper III) while Stx2 has 
been shown to bind well to NAc-Pk  (Flagler et al., 2010). It is not known if these 
determinants are only carried by glycolipids (Yang et al., 1994, Gallegos et al., 2012).    
Both Stx1 and Stx2 appears to bind to Gb3Cer in vivo while in vitro binding of Stx2 to 
Gb3Cer or Pk (without ceramide) is weaker than that of Stx1 (Gallegos et al., 2012). It 
has been shown that Stx2 binding may depend on other parts of Gb3Cer than the 
carbohydrate moiety alone, such as other glycolipids, cholesterol and 
phosphatidylcholine (Gallegos et al., 2012).  The difference in binding specificity may 
be important since Stx2 is more toxic in vivo and is more closely associated with 
development with HUS than Stx1. It has been noted that the clustering of Gb3Cer in 
lipid rafts is proportionally higher in kidney compared to other sites (Lingwood, 1994, 
Khan et al., 2009). One can thus speculate if the higher toxicity of the Stx2 toxin may 
be explained by the specific targeting of Stx2 to Gb3Cer in lipid rafts in the glomerular 
cells of the kidney. Once concentrated to the kidney, the lipid rafts may in addition 
contribute to a more efficient endocytosis of the toxin compared to no clustered 
endocytosis in other sites (Falguieres et al., 2001).   
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Figure 7 Synthesis of the human P blood group system. Gb3Cer (Pk antigen) is the native receptor of 
Shiga toxins. In paper III strong binding of Stx1 and Stx2 to PSGL-1/mIgG2b carrying multiple copies of 
P1 determinant was shown in a Biacore assay.  
 
7.5 Pathogenesis	  
The most common symptom of infections caused by STEC is hemorrhagic colitis. 
Infection occurs by ingestion of food or contact with infected humans or animals (Tarr 
et al., 2005). Risk groups include children and elderly that are more likely to develop 
complications, such as HUS. HUS is characterized by microvascular thrombosis with 
consequent thrombocytopaenia, haemolytic anaemia and acute renal failure (Noris et 
al., 2012, Melton-Celsa et al., 2012). HUS is mostly associated with Shiga toxin-
producing E. coli (STEC) that produces the Stx2 toxin. Occasionally out brakes occurs 
with STEC that cause considerably higher rates of HUS. This has been observed for 
O157:H7 and O104:H4 (Tarr et al., 2005, Frank et al., 2011), where the latter strain 
caused HUS in 22% of the patients (Frank et al., 2011). The mechanism of how STEC 
cause HUS is complex. In brief, during STEC infection, Shiga toxin triggers 
complement hyper activation, possibly via up regulation of P selectin on endothelial 
cells and direct involvement with complement regulatory molecules (Noris et al., 
2012). Inflammation is induced and platelet activation leads to microvascular 
Pk transferase
P transferase
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G1,4GalTP1 transferase
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thrombosis (Noris et al., 2012). Since STEC produce other virulence factors in addition 
to Shiga toxin, these may also contribute to disease.  
 
7.5.1 Shiga	  toxin	  mechanism	  of	  action	  
The detailed description of the mechanism of action of Shiga toxins is beyond the scope 
of this thesis. Briefly, the A subunit inactivates the 60S ribosomal subunit which 
effectively inhibits protein synthesis in the target cell. This is achieved by the RNA N-
glycosidase activity of the A subunit which removes an adenosine from the 3’region of 
the 28S rRNA. ((Mulvey et al., 2003) and references within).    
 
7.6 Traditional	  treatment	  and	  novel	  inhibitors	  
Hospitalized STEC and HUS patients have traditionally been limited to supportive 
treatment, resorting to the notion that the best way to prevent HUS is to prevent STEC 
infection (Tarr et al., 2005). Recent studies have indicated that monoclonal anti-C5 
antibodies that target the hyperactive complement system in HUS show promising 
results (Noris et al., 2012). Other means to treat STEC include different strategies to 
inhibit the Shiga toxin either by preventing attachment (receptor mimics (Kitov et al., 
2008, Mulvey et al., 2003, Nishikawa et al., 2005), or monoclonal antibodies (Bitzan et 
al., 2009, Lopez et al., 2010)) or inhibiting the intracellular effector function of the 
toxin (inhibitory peptides and chloroquine  (Nishikawa et al., 2006) (Dyve Lingelem et 
al., 2012)). The receptor mimics studies have indicated the need of a multivalent 
inhibitor in order to achieve inhibition in vivo since a clinical phase III trial with 
Synsorb-Pk showed no protection against HUS (Trachtman et al., 2003). No licensed 
drug against Shiga toxin is yet approved. In paper III we analyze the binding of Stx1 
and Stx2 to a potential novel inhibitor that is based on a recombinant fusion protein that 
is presenting the P1 epitope in multiple copies.  
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8 Aims of the present study 
The general aim of the thesis was to explore the O-glycosylation capacity of insect cells 
and to develop novel inhibitors of antibodies, bacterial toxins and viral receptors that 
bind carbohydrate determinants.  
 
Specific aims: 
I. Determine the O-glycosylation capacity of Spodoptera frugiperda (Sf9) and 
Trichoplusia ni (High-five) cells by analyzing the O-glycosylation of the 
recombinant PSGL-1/mIgG2b mucin-type fusion protein expressed in those 
cells.  
 
II. In glyco-engineered Chinese Hamster Ovary cells produce a novel multivalent 
immunoadsorber of chain type-specific anti-A and anti-B antibodies 
comprised of the PSGL-1/mIgG2b mucin-type fusion protein with different 
blood group A and B determinants on different core saccharide chains.  
	  
III. Produce a multivalent potential inhibitor of Shiga toxin by expressing the 
PSGL-1/mIgG2b mucin-type fusion protein with blood group P1 determinants 
in glyco-engineered Chinese Hamster Ovary cells.  
	  
IV. Produce a multivalent potential inhibitor of avian influenza hemagglutinin in 
glyco-engineered Chinese Hamster Ovary cells by expressing the PSGL-
1/mIgG2b mucin-type fusion protein substituted with terminal Siaα2,3Gal.  
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9 Methodological	  considerations	  
 
9.1 Cell	  cultures	  
The insect cells Sf9 and Hi-5 were grown in serum-containing culture medium in T-
flasks (small scale) and suspension cultures (large scale) in Erlenmeyer flasks. The cells 
were grown in a shaker-incubator at 27ºC without CO2 control.  The excretion of 
PSGL-1/mIgG2b to the culture medium was in the range of 1-2 mg/L. The insect cell 
culture conditions were not optimized and did not give yields that would be needed for 
large scale commercial production of recombinant proteins, such as with the 
baculovirus expression vector system (BEVS) (Drugmand et al., 2012).  The 
mammalian cell cultures were grown under conditions that were monitored more 
closely. The blood group A producing cells (paper I) and 293-P, C-PSLex and C-P55 
(paper IV) were grown in Wave bioreactors while blood group B producing cells (paper 
II) were grown in Erlenmeyer flasks. All mammalian cells were grown in serum-free 
culture medium. The Wave bioreactor is a single use bioreactor cell culture system that 
allows the control of temperature, CO2, O2 and the addition of culture medium. The 
glucose, glutamine and pH levels were monitored every day. The aeration and mixing 
of the cells is accomplished through a tilting table that creates waves inside the plastic 
culture bag. The production level of PSGL-1/mIgG2b was more dependent on selecting 
high- producing clones rather than the culture technique (Wave vs. suspension cultures) 
and was between 5-40 mg/L for the different clones.  
 
9.2 Constructs	  and	  transfections	  
In paper I the cDNA encoding the PSGL-1/mIgG2b was cloned into the expression 
vector pIZ/V5-His (Invitrogen) as described previously (Gustafsson, 2005). The fusion 
protein expression is under the control of the opIE2 promoter, derived from the 
baculovirus Orgyia pseudotsugata multicapsid nuclear polyhedrosis virus (OpMNPV). 
Positive cells were batch-selected using zeocin selection agent. The vector has been 
demonstrated to allow the expression in a range of insect cells. However, we failed to 
establish a stable Mamestra brassicae cell line with this vector, even though a range of 
transfection techniques were tested (different liposome formulations, nucleoporation 
and magnetic nanoparticles).  The vectors for the stable mammalian cell lines used in 
paper II are listed in the supplemental table S1 of the same paper. The backbone of the 
vectors was CDM8 with CMV or EF1α promoters driving the expression of the desired 
gene (Liu et al., 2005). Since individual plasmids encoding PSGL-1/mIgG2b and each 
of the glycosyltransferases were used, up to five selection drugs were used 
simultaneously (e.g. for selection and culture of the C-PB1 clone, paper II). The 
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transfections were carried out with Lipofectamine 2000 CP (Invitrogen) and single-cell 
clones were selected as described in the supplemental data of paper II. 
 
9.3 Purification	  of	  PSGL-­‐1/mIgG2b	  
The purifications of the mucin-type fusion protein are described in detail in each paper. 
The relative ease of purification was dependent on the cellular origin and concentration 
of PSGL-1/mIgG2b. The mucin-type fusion protein was purified with affinity- and 
gelfiltration chromatography prior to dialysis against water and subsequent analysis. 
PSGL-1/mIgG2b derived from insect cells was affinity purified on anti-IgG (whole 
molecule) agarose (Sigma-Aldrich) columns that capture the IgGFc-part of the fusion 
protein while PSGL-1/mIgG2b derived from mammalian cell lines was purified on 
protein A columns (MabSelecSure, GE Healthcare). Protein A binds to the Fc-portion 
of antibodies. However, the Protein A columns proved to be less efficient for 
purification of the insect cell-derived fusion protein. It is possible that the glycosylation 
may affect the binding to the affinity columns. Other conceivable reasons for the 
difference in Protein A binding is the fact that cleared insect medium was loaded 
directly on the affinity columns and that the PSGL-1/mIgG2b concentration in the 
medium was relatively low.  The large-scale mammalian Wave cultures were grown in 
serum free culture medium. The cells were removed with microfiltration, concentrated 
(ultrafiltered) and buffer exchanged (diafiltered) to PBS before being loaded on the 
protein A column.  
 
9.4 Specificity	  of	  antibodies	  	  
Monoclonal antibodies recognizing terminal carbohydrate determinants on the mucin-
type fusion protein were used in paper I and II. In paper I, anti-Tn monoclonal 
antibodies used in Western blot indicated the presence of GalNAcα-Ser/Thr on PSGL-
1/mIgG2b produced in Hi-5 and CHO cells. In paper II, monoclonal antibodies were 
used to detect the blood group A determinants on the type 1, 2 and 3 saccharide chains 
and the blood group B determinant using Western blotting. The MS analysis provided 
the sequence of glycans carrying tentative blood group antigens, and the monoclonal 
anti-A antibodies could confirm the presence of the specific determinant (linkage 
information). Occasional discrepancies between Western blot and LC-MS are discussed 
in paper I and II. 
 
9.5 Lectins	  
Lectins were used to detect specific terminal glycans on the mucin-type fusion protein. 
Lectin Western blot was used in paper I-II and IV, and in addition a lectin array chip 
was used in paper I. Lectins have preferred glycan binding partners but may also bind 
to secondary glycan targets. The risk of cross-reaction is increased if the conditions are 
 48 
not optimal (some lectins requires metal ions such as Ca2+, Zn2+ and Mn2+) or if the 
ligands are supplied in very high concentration. We have noticed that the lectin binding 
may also depend on how the carbohydrate determinant is presented, that is, the inner 
carbohydrate chain and the protein that carries the carbohydrate (neoglycoconjugate vs. 
glycoprotein) may influence recognition. In the Western blot experiments positive and 
negative controls were therefore included. Since the lectins cannot give linkage 
information for individual glycans on the fusion protein, this strategy is more reliable if 
the glycosylation is less abundant.  
 
9.6 Quantification	  of	  PSGL-­‐1/mIgG2b	  
The concentration of purified PSGL-1/mIgG2b was determined with a sandwich 
enzyme-linked immuno sorbent assay (ELISA).  ELISA plates were coated with a goat 
anti-mouse IgGFc antibody upon which PSGL-1/mIgG2b was added after blocking of 
non-specific binding sites. After washing, a goat anti-mouse horseradish peroxidase 
(HRP) conjugated antibody was used for detection. A dilution series of IgG2b antibody 
with known concentration was used to determine the concentration of unknown PSGL-
1/mIgG2b. We have previously noticed that the assessed concentrations of PSGL-
1/mIgG2b and detections with Western blot have varied depending on which cell line 
PSGL-1/mIgG2b was derived from. An example is the comparatively weak detection of 
PSGL-1/mIgG2b with anti-PSGL-1 when produced in Pichia pastoris ((Gustafsson et 
al., 2011) and paper IV). The fusion protein produced in these cells is heavily 
glycosylated with mannose. We therefore suggest that the glycosylation of the fusion 
protein may partly mask the epitopes recognized by the antibodies.  The concentration 
of PSGL-1/mIgG2b determined with the ELISA method should therefore be interpreted 
with caution.  
 
9.7 Surface	  Plasmon	  resonance	  
 
9.7.1 Biacore	  biosensor	  
Surface Plasmon Resonance (SPR) is a technique that measures the interaction of 
molecules in real-time in a label-free system. This technique was used to measure the 
interaction between the mucin-type fusion protein and recombinant avian influenza 
hemagglutinin (paper III) and Shiga like toxins (paper IV).  In the Biacore instrument, 
one molecule is immobilized on the sensor chip surface (ligand) and the other molecule 
(analyte) is passed over the surface at different concentrations in a number of different 
injection cycles. Utilizing the SPR phenomenon, interaction of ligand and analyte is 
detected by the instrument via a change in the refractive index. The change in angle of 
reflected light is proportional to the mass of the analyte at the surface (Figure 8).  
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Figure 8 Illustration of how the SPR phenomenon is used in a SPR instrument (e.g. Biacore) in order to 
measure the interaction between an immobilized ligand and an analyte that is passed over the surface by a 
continuous flow of liquid. The interaction of the analyte in proximity of the surface causes a change in the 
refractive index. The resulting change in angle of reflected polarized light is detected and translated to a 
response signal that is plotted in a graph (sensorgram) on a computer screen in real-time.  
 
The interaction of the ligand and injected analyte is plotted in a graph called a 
sensorgram with binding levels reported as response units (RU) (Figure 9).  
 
Gold surface  
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Figure 9 Schematic illustration of the different steps of an injection cycle in a sensorgram graph. Any 
change in molecule density at the chip surface is plotted as curve responses in the sensorgram. When 
buffer is flowing over the chip no response shift is recorded (flat line). This is referred to as the baseline. 
Injection of analyte results in build-up of analyte-ligand complexes that is plotted as a positive slope 
curve as more and more analyte becomes bound (association phase). As equilibrium is being reached the 
curve flats out and eventually reaches steady-state (flat curve). When analyte is no longer injected the 
analyte-ligand complexes starts to decay.  The subsequent dissociation of analyte from the surface is 
recorded as a negative slope curve. In order to remove all bound analyte molecules, regeneration of the 
surface with regeneration buffer may be needed. When the baseline is restored to pre-injection levels a 
new injection cycle may be started.  
 
Injection of analyte and subsequent running buffer, gives a binding curve with an 
association phase (analyte-ligand complex formation) and a dissociation phase 
(analyte-ligand complex dissolving) (Figure 9). In order to re-use the ligand surface for 
an additional injection cycle, all bound analyte must have been removed. If this is not 
achieved with buffer injection, the surface needs to be regenerated with more rigorous 
measures. The regeneration needs to be strong enough to remove all bound analyte but 
without removing or denaturing the immobilized ligand.  From the binding curves, 
association- and dissociation kinetic constants, ka and kd, can be calculated by fitting the 
curves to theoretical binding models. The (affinity) equilibrium dissociation constant, 
KD, can be derived from ka and kd or from curves that have reached equilibrium (steady-
state). Affinity and kinetic constants in paper III and IV were determined with the 
Resonance signal (RU) 
Steady-state 
Dissociation Association 
Baseline  Baseline 
Regeneration kinetics
Time (s)
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Scrubber 2 and BiaEvaluation softwares. The calculations are based on the equations 
listed below.  
 
9.7.2 Determination	  of	  affinity	  and	  kinetic	  constants	  
Calculations of the affinity (how strong the complex is) and kinetics (how fast the 
interaction is) of the analyte-ligand interactions were calculated according to a 1:1 
binding model in both paper III and IV. The mucins and the Shiga toxin / 
hemagglutinin have multiple binding sites, which are not accounted for in the simple 
1:1 binding model. Even if a model adapted for multivalent interactions existed, it 
would not be feasible to use it because the exact valency of the mucins and the 
immobilized Shiga toxin and H5 is not known in this system. Calculations of KD that 
are based on steady-state models should ideally only be performed when all curves 
have reached equilibrium. The concentration range of the injections should yield curves 
with curvature and reach saturation at high concentrations. If none of the curves are 
close to reaching saturation the calculated KD value may be lower than the real KD 
value. However, if the curves do not reach steady-state, the calculated KD value will be 
higher than the real value.  
 
Rate equations for 1:1 kinetics 
 
 
 
( 1 ) 
 
 Association:   d ABdt = k! ∗    A ∗    B   ( 2 ) 
   
 
 Dissociation:  −d ABdt =   k! ∗ AB   ( 3 ) 
 
 Net  rate  equation:   d ABdt =   k! ∗    A ∗ B −   k! ∗    AB   ( 4 ) 
                                     M/s      M-1s-1  M      M       s-1       M  
 
Where 
ka = association rate constant [M-1 s-1) 
kd = dissociation rate constant [s-1] 
 
 
⇌ A  +  B ABkakd
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Equilibrium constants 
 
At equilibrium: 
Association = dissociation 
 
 
ka    ∗  [A] ∗ [B] = kd ∗ [AB] ( 5 ) 
M-1s-1   M     M     s-1      M  
 
The equilibrium constants: 𝐾! =    k!k! =    ABA ∗    B  the equilibrium association constant [M-1]  ( 6 ) 𝐾! =   k!k! =    A ∗    BAB  the equilibrium dissociation constant [M] ( 7 ) 
 
9.7.3 Biacore	  nomenclature	  
A is the analyte in solution. The free concentration is constant by continuous flow 
AB is the complex. Concentration of complex is measured as R in RU 
B is the ligand on the surface. Total concentration can be expressed in RU as maximum 
binding capacity Rmax. Free concentration is Rmax - R 
 
 
 
( 1 ) 
d ABdt  = k! ∗    A ∗ B − k! ∗    AB   ( 8 ) dRdt                =   k! ∗     C     ∗      R!"# − R     ∗     k!     ∗     R ( 9 ) 
RU/s                 M-1s-1   M            RU              s-1      RU  
 
A has one binding site and reacts with immobilized ligand. 
B has n identical and independent binding sites.  
 
9.7.4 Experimental	  design	  
Achieving high quality data from SPR experiments requires that many parameters have 
been considered. In addition to Biacore handbooks and courses, help can be found 
elsewhere. The www.sprpages.nl (last accessed March 24 2013) homepage written by 
Arnoud Marquart give ample information on how to avoid pitfalls and how to design 
experiments that yields reliable results. Rebecca L. Rich and David G. Myszka have 
⇌ A  +  B ABkakd
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each year published a survey of the optical biosensor articles, showing both good and 
bad examples of experimental designs and results (Rich and Myszka, 2006). In paper 
III, the shortage of recombinant hemagglutinin (HA) in practice meant it had to be 
immobilized on the chip surface, rather than being flowed over the surface.  The HA 
protein is meta-stable and the conformational change which is needed for membrane 
fusion during infection is triggered easily, especially by low pH (Skehel et al., 1982) 
(see separate section above about influenza hemagglutinin) therefore ionic strength 
regeneration was used. The instability of the chip surfaces precluded sequential runs of 
different analytes on the same surface while in paper III, the immobilized Stx1/2 was 
stable enough to allow direct comparison of successive analytes (PSLGL-1/mIgG2b and 
Pk-albumin).  
 
9.8 Mass	  spectrometry	  
In paper I-IV we have used mass spectrometry to determine the composition, sequence 
and in some cases the linkage information of O-glycans released from PSGL-1/mIgG2b.   
Successful sequencing of individual O-glycans in complex mixtures was demonstrated 
with both direct injection electrospray ionization mass spectrometry (ESI-MS) (paper I) 
and liquid chromatography mass spectrometry (LC-MS) (paper I-IV). In paper I ESI-
MS was performed on a LCQ ion-trap instrument in positive mode on O-glycans 
released from PSGL-1/mIgG2b that were derivatized by permethylation in order to 
increase ionization efficiency and facilitate the interpretation of the fragmentations 
(Kenny et al., 2013, North et al., 2009, Ashline et al., 2005). Since isomeric ions were 
not separated by a preceding column, the sequence of isomeric ions was deduced by 
successive MS-MS fragmentation that generated unambiguous fragments (paper I).  
Some disadvantages with the ESI-MSn analysis included the relative insensitivity (0.5-
1mg minimum glycoprotein starting material), the occasional problem of determining 
the sequence of isomeric glycans and the m/z  [M + 30]+ artifact that sometimes made 
the interpretation of the MS spectrum uncertain.  LC-MS and LC-MS2 analysis was 
used to characterize non-derivatized released O-glycans on a LTQ ion-trap mass 
spectrometer coupled to a graphitized column that often separated isomeric glycans 
(paper I-IV).  The method proved to be robust, sensitive and versatile and gave as much 
structural information as ESI-MSn and required much less starting material (as little as 
10µg fusion protein).  LC-MS allowed the detection of the substitutions sulfate and 
phosphocholine, which were not detected in the analysis of permethylated glycan 
derivatives (paper I).  Carbohydrates carrying the charged substitutions were probably 
lost during the water: chloroform wash-up of the samples after the permethylation step. 
The charged residues may have migrated to the water phase, while the permethylated 
glycans stayed in the chloroform phase. By comparing the LC-MS2 fragment spectra 
with known standards the linkage (paper I-IV), substitution- and monosaccharide 
identity of several O-glycans (paper I) were deduced.  
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Some minor artifacts were noticed in the LC-MS spectra that were likely 
introduced during the release and wash up of the samples. They included a 
contaminating hexose ladder, de-N-acetylation m/z [M – 42]-, O-acetylation m/z [M – 
42]-, peeling (sugars without GalNAcol) and loss of water m/z [M – 18]-.  
Mass spectrometry is not a quantitative method since the ionization 
efficiency of different glycans is not completely uniform. Occasionally, LC-MS failed 
to detect glycan structures the presences of which were proposed by Western blotting 
with monoclonal antibodies, for example the Tn antigen (GalNAcαSer/Thr, paper I) 
and anti-A type 2 (paper II). 
 
9.8.1 Interpretation	  of	  mass	  spectrometry	  data	  
The free software Glycoworkbench (free downloadable java tool, 
www.glycoworkbench.com) computer program was used to draw glycan cartoons and 
generate fragmentation in silico (Ceroni et al., 2007, Ceroni et al., 2008, Damerell et 
al., 2012). The annotated MS2 spectra from paper I-IV have been submitted to the LC-
MS2 database (www.unicarb-db.com) for public access. The database contains the 
negative mode LC-MS2 spectra of non-derivatized glycans presented in graphical 
format and as peak lists; in principle showing the “fingerprint” of each glycan.  
 
9.9 DMB	  RP-­‐HPLC	  
In paper I reverse-phase high performance liquid chromatography (RP-HPLC) on 
released DMB-labeled sialic acid was performed by the Glycotechnology Core 
Resource at the University of California, San Diego. Low amounts of Neu5Ac and 
Neu5Gc were detected in both Sf9 and Hi-5. This ultrasensitive technique has proved 
to be the source of some controversy. Zeleny et al. have reported that previous claims 
of sialic acid in a variety of sources (plants) may be due to inadvertent contamination 
during the sample work-up (Zeleny et al., 2006). In their study, they could detect sialic 
acid even in the blanks. The author’s conclusion was that the level of sialic acid in 
plants was in the same range as the background level of the method. Blanks (water) 
were treated in parallel to the insect derived samples and did not contain any detectable 
levels of sialic acid. The possible source of the sialic acid is further discussed in paper I.   
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10 Results	  and	  discussion	  
 
10.1 PSGL-­‐1/mIgG2b	   with	   tailored	   glycosylation	   produced	   in	  
	  glyco-­‐engineered	  cell	  lines	  	  
In this thesis all four papers involve the use of stable cell lines that produce a mucin-
type fusion protein composed of the extracellular part of P-selectin glycoprotein ligand-
1 fused to the Fc part of mIgG2b to form the PSGL-1/mIgG2b protein.  The mucin-type 
protein was originally constructed in order to produce a multivalent scaffold that would 
allow the adsorption of specific anti-carbohydrate antibodies, in this case anti-
Galα1,3Gal antibodies. The PSGL-1/mIgG2b dimer has 6 potential N- and 106 potential 
O-glycosylation sites thus constituting a scaffold for a multivalent display of 
carbohydrates.  The host cell determines the specific glycosylation of the mucin-type 
glycoprotein. The intended use of the glycoprotein, that is the desired glycosylation, 
dictates the choice of expression system.  In addition, glyco-engineering of cell lines 
(CHO cells in particular) has proven to be a powerful technique to produce specific 
carbohydrate determinants. This is achieved by transfecting the cells with plasmids 
encoding specific glycosyltransferases that enables the cells to produce complex 
carbohydrates beyond their natural capacity (Figure 10). In paper I, PSGL-1/mIG2b was 
expressed in Sf9 and Hi-5 insect cell lines and was used as a probe to analyze the O-
glycosylation capacity of these cells. In paper II, glyco-engineered CHO cell lines were 
used to produce the fusion protein carrying blood group determinants on different outer 
core saccharide chains. Paper III and IV also relied on the production of glyco-
engineered CHO cells in order to produce the fusion protein substituted with the P1 
carbohydrate determinant or terminal Siaα2,3Gal determinants, which are binding 
partners of Shiga toxin and the avian influenza H5 hemagglutinin, respectively. 
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Figure 10 Overview of the establishment of cell lines expressing the mucin-type fusion protein  
PSGL-1/mIgG2b with multiple copies of O-linked carbohydrates. The glycosylation of the mucin-type 
protein may be controlled either by producing the protein in cell lines with a desired glycosylation 
capacity or by modifying the glycosylation machinery of the cells by transfecting them with additional 
plasmids encoding specific glycosyltransferases.  
 
10.2 The	  glycosylation	  in	  insect	  cells	  (paper	  I)	  
 
10.2.1 Aim	  and	  background	  
Sf9 (Spodoptera frugiperda) and Hi-5 (Trichoplusia ni) are two commercially 
important cell lines that are extensively used for the production of recombinant proteins 
for research use and increasingly as a source of human vaccine components (Roldao et 
al., 2011) (Cox, 2012). The aim of paper I was to investigate the O-glycosylation 
capacity of Sf9 and Hi-5 cells in order to explore their potential as expression systems 
of therapeutic proteins.  
 
10.2.2 Production	  of	  PSGL-­‐1/mIgG2b	  
Hi-5 insect cells were engineered as described previously (Gustafsson, 2005), and Sf9 
cells were generated in the same manner. The fusion protein was excreted to the cell 
medium and purified with affinity and gel filtration chromatography.  
 
10.2.3 Structural	  characterization	  of	  carbohydrate	  epitopes	  on	  PSGL-­‐1/mIgG2b	  
O-glycans released from the heavily glycosylated PSGL-1/mIgG2b protein produced in 
Sf9 and Hi-5 cells were characterized with ESI-MSn and LC-MS2. LC-MSn analysis of 
N-glycan O-glycan S disulfide bond
S-S
PSGL-1/mIgG2b plasmid
Glycosyltransferase plasmid
Recombinant multivalent
mucin type fusion proteinGeneration of stable cell line
PSGL-1 domain
mIgGFc domain
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known standards together with monosaccharide analysis, lectin array chip and Western 
blot were used to give additional structural information.  
 
10.2.4 Sf9	  and	  Hi-­‐5	  O-­‐glycosylation	  is	  complex	  and	  diverse	  
The structural analysis of O-glycans released from PSGL-1/mIgG2b produced in Sf9 
and Hi-5 cells revealed a large repertoire of diverse glycans, which is in contrast to 
previous findings of only smaller O-glycans in these cells such as the T- 
(Galβ1,3GalNAcαSer/Thr) and Tn antigen (GalNAcαSer/Thr) (Lopez et al., 1999, 
Thomsen et al., 1990). We assigned 29 and 21 O-glycans in Hi-5 and Sf9, respectively. 
Some of the structures shared the sequence with previously reported O-glycans in 
Drosophila melanogaster embryos and salivary mucins from Wasps, but the majority 
had not been reported previously (Aoki et al., 2008, Aoki and Tiemeyer, 2010, Maes et 
al., 2005, Garenaux et al., 2011). Negative mode LC-MS of non-derivatized O-glycans 
proved to be a sensitive and specific method to assign the sequence of most glycans and 
for a few glycans also the linkage and identity of the terminal monosaccharides. 
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10.2.5 A	  range	  of	  core	  structures	  
The majority of all O-glycans detected on both cell lines were built upon the three core 
structures HexA-GalNAcol, Hex-GalNAcol (tentatively core 1), and  
HexA-(Fuc-)GalNAcol, where the first core structure was most prominent (Figure 12).  
In addition a single HexNAc-HexA-Fucol structure and small amounts of tentative core 
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2 extended structures were detected (Figure 12). In comparison, the mammalian CHO 
cells produce O-glycans that are almost completely core 1 based, unless glyco-
engineered (paper II-IV). The unusual addition of Fucose linked to the core GalNAc 
was noted and has previously been observed in Wasps and mutant nematodes 
(Garenaux et al., 2011, Palaima et al., 2010). The Tn antigen was detected in Hi-5 
Western blot but was not observed in the mass spectrometric analysis of Sf9 and Hi-5 
derived O-glycans.   
 
 
 
Figure 12 Examples of O-glycan cores and extended structures thereof derived from PSGL-1/mIgG2b 
produced in Sf9 and Hi-5 cells. The occurrence of each structure in the cell lines is indicated. Dashed 
squares indicate the unusual GalNAc4HexNAc (Sf9) epitope and the HexNAc-HexA-Hex repeat (Hi-5).  
 
10.2.6 Insect	   cell	   O-­‐glycans	   are	   substituted	   with	   charged	   monosaccharides	  
and	  functional	  groups	  
Glucuronic acid (GlcA) was prevalent (LC-MS and monosaccharide profile with 
HPAEC-PAD) in both Sf9 and Hi-5 derived O-glycans, while only trace amounts of 
sialic acid were detected (RP-HPLC of DMB derivatized sialic acid).  Today there is a 
consensus that insect cells have very limited capacity to produce sialic acid unless 
genetically engineered (Voss et al., 1993, Marchal et al., 2001, Hillar and Jarvis, 2010). 
Previous studies of O-glycans in Drosophila melanogaster embryos and Drosophila 
Schneider-2 cells (S2) have also found glucuronic acid (Aoki et al., 2008, Breloy et al., 
2008). One can speculate if these negatively charged hexuronic acid residues are a 
general theme of insects and that GlcA may have an analogous role to sialic acid in 
mammals. However, several observations indicate that this is an over simplification.  
GlcA was not detected in Wasp-derived O-glycans and GlcA does not seem to 
contribute to the negative surface charge of S2 cells (Breloy et al., 2008, Garenaux et 
al., 2011). Further, GlcA is detected in a range of positions in glycan chains, in contrast 
to the terminal position of sialic acid in mammals (paper I and (Aoki et al., 2008)). The 
capping of terminal residues with charged resides appears to be related to the specific 
n
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interaction with other molecules. The binding of a charged residue that fit into the 
hydrophobic pocket in the binding partner has been observed in several receptor-ligand 
pairs including carbohydrate-glycoprotein interactions (Yeh et al., 2001). The 
negatively charged sulfate substitution was detected on O-glycans derived from PSGL-
1/mIgG2b produced in both Sf9 and Hi-5 cells. Notably, the sulfate was only detected 
on terminal residues as indicated by LC-MS2. The zwitterionic phosphocholine (PC) 
substitution was detected on O-glycans released from PSGL-1/mIgG2b produced in Sf9 
cells (LC-MS2 in positive mode and anti-PC Western blot) but also in protein extracts 
of Sf9 cells that were not transfected with PSGL-1/mIgG2b plasmids (anti-PC Western 
blot). To our knowledge, PC has not been reported previously on glycoproteins in 
insect cells. In Wasps a related phospoethanolamine (2-aminoethyl phosphate group) 
substitution has been found on O-linked glycans (Maes et al., 2005).  The role of PC in 
Sf9 cells is not known. However, PC is prevalent on nematode glycans and has been 
demonstrated to be a potent immune modulator (Lochnit et al., 2000, Harnett et al., 
2008, Harnett and Harnett, 2008).  
 
10.2.7 Insect	  glycosylation	  compared	  to	  other	  organisms	  
Paper I extends the list of known O-glycans in Sf9 and Hi-5 cells and insects in general. 
The majority of the detected structures will be recognized as foreign if introduced in 
humans. In particular, the PC modification found on some Sf9 derived O-glycans might 
cause adverse reactions.  This emphasizes that the glycosylation of unmodified insect 
cells is unsuitable for the production of therapeutic glycoproteins. Human O-
glycosylation is very complex, based on many core structures (table 1), and the cores 
are usually extended with additional determinants not detected in insect cells such as a 
range of blood group determinants, poly-N-acetyllactosamine structures and terminal 
sialic acid.  Actually, insect cells have more in common with nematodes and plants 
with regard to glycosylation. These organisms largely lack sialic acid synthesis and 
display mainly less complex N-glycosylation (truncated, paucimannose type) compared 
to humans, and terminally linked PC is a prevalent feature of nematodes (Harnett et al., 
2010, Poltl et al., 2007). The O-glycans of nematodes also share some structural 
features with insects because several GlcA containing structures are the same or very 
similar to those detected in paper I.  
While human N-glycosylation is often complex with extensive branching 
and capping with terminal N-acetyllactosamine and sialic acid, insects mainly produce 
non-sialylated truncated N-glycans with fucose α1,3 or α1,6-linked to the chitobiose 
core. Fucose α1,3-linked to core GlcNAc is non-human and potentially immunogenic 
(Altmann, 2007). However, detailed analysis on Drosophila embryos has revealed the 
presence of hybrid-, complex biantennary, and triantennary N-glycans (Aoki et al., 
2007). Very low levels of terminal sialic acid suggest a limited and specialized 
expression pattern in Drosophila (Aoki et al., 2007). Studies on S. frugiperda cells 
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suggest the presence of hybrid N-glycans (Ogonah et al., 1996), while the analysis of a 
recombinant murine antibody in T.ni cells indicated the presence of complex type 
(terminal Gal and GlcNAc), hybrid, and paucimannosidic type N-glycans (Hsu et al., 
1997). The wide range of O-glycan structures detected in both Sf9 and Hi-5 lead us to 
suggest that the efforts to “humanize” these cell lines with regard to their N-
glycosylation (Harrison and Jarvis, 2006), (Palmberger et al., 2012, Aumiller et al., 
2012, Aumiller et al., 2003, Jarvis et al., 1998)  should also be expanded to include 
their O-glycosylation. This may involve both the addition of human 
glycosyltransferases but possibly, mainly the removal of unwanted 
glycosyltransferases. This type of work would benefit greatly by the availability of the 
genome sequences of these cells. The Bombyx mori genome and transcriptome is now 
available but corresponding efforts have not reached as far with the Sf9 and Hi-5 cells 
(Li et al., 2012, Xia et al., 2009, Xiang et al., 2010).  
Since we use the recombinant PSGL-1/mIgG2b protein as a probe to 
investigate the O-glycosylation capacity of Sf9 and Hi-5 cells, one may ask if the 
detected glycans are representative of the endogenous glycosylation. The answer 
depends on what kind of endogenous protein the comparison would be made with 
because the glycosylation of different proteins vary greatly. The cell lines are germ 
line derived and thus potentially less differentiated compared to cells derived from 
tissues. In the artificial cell culture system the glycosylation does not have biological 
constraints as cells would in living organisms. It is possible that the lack of inhibitory 
or stimulatory signals from the surrounding environment can lead to increased or 
decreased glycosylation.  
 
In conclusion, Paper I has revealed that the O-glycosylation of Sf9 and Hi-5 insect 
cells is more complex than previously realized. This further underscores that 
unmodified Sf9 and Hi-5 cells may not be suitable for the production of therapeutic 
glycoproteins.  
 
10.3 Mucin-­‐type	   proteins	   as	   adsorbers	   of	   anti-­‐A	   and	   anti-­‐B	   antibodies	  
(paper	  II)	  
 
10.3.1 Aim	  and	  background	  
The overall aim of paper II was to produce blood group A and B determinants on 
different outer core saccharide chains presented in multiple copies on the PSGL-
1/mIgG2b mucin-type protein. We suggest that the multivalent presentation of the 
carbohydrate epitopes increase their avidity to chain type-specific anti-A and anti-B 
antibodies compared to A and B determinants of low valency. The mucins may be used 
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as efficient adsorbers of chain-specific anti-A and anti-B antibodies and as substrates 
for the quantification and specificity-determination of ABO antibodies.  
 
10.3.2 Establishment	  of	  glycan-­‐tailored	  CHO	  cells	  expressing	  the	  A	  or	  B	  blood	  
group	  determinants	  on	  different	  outer	  core	  saccharide	  chains	  
The cells were transfected with plasmids encoding PSGL-1/mIgG2b, core 2 
(β1,6GlcNAc-T1) or core 3 (β1,3GlcNAc-T6 and β1,3Gal- T5) enzymes together with 
α1,2Fuc-T1 or α1,2Fuc-T2 and the A or B gene-encoded α1,3GalNAcT or α1,3Gal-T, 
respectively. The complete transfection schedule is shown in Figure 13. The fusion 
proteins were excreted to the cell medium and purified with affinity and gel filtration 
chromatography. 
 
 
 
Figure 13 Transfection table to generate stable transfectants of CHO-K1 and Lec2 cells. Transfected 
cDNAs are indicated above the arrows, and cell lines selected for large-scale cultivation and further 
analysis are given in squares (clone name in parenthesis). Abbreviations as follows: FUT1, α1,2-
fucosyltransferase-1; FUT2, α1,2-fucosyltransferase-2; C2, β1,6-N-acetylglucosaminyltransferase-1; C3, 
β1,3-N-acetylglucosaminyltransferase-6; GalT5, β1,3-galactosyltransferase-5; GalNAcT, α1,3-N-
acetylgalactosyltransferase; GalT, α1,3-galactosyltransferase.  
 
10.3.3 Structural	  characterization	  of	  carbohydrate	  epitopes	  on	  PSGL-­‐1/mIgG2b	  
The glycosylation of purified mucin-type proteins was characterized with anti-A/B and 
lectin Western blot and LC-MS2 on released O-glycans. The annotation of the blood 
group A determinants was largely facilitated by the availability of chain-specific anti-A 
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antibodies (anti-A type 1, 2 and 3, respectively) and knowledge of the available 
glycosyltransferases in the well-studied CHO cells. The blood group B determinants 
were determined with anti-B Western blot (unspecified chain) and LC-MS2. The 
combined results indicated that A and B type determinants were produced on type 1 
(Galβ1,3GlcNAc-), type 2 (Galβ1,4GlcNAc-) and type 3 (Galβ1,3GalNAcα) chains. 
The obtained tentative blood group determinants detected in each clone are shown in 
Figure 14. The production of blood group determinants based on core 3 (conversion 
from core 1 to core 3 by transfection with β1,3GlcNAc-T6) was efficient while blood 
group determinants based on core 2 (conversion from core 1 to core 2 by transfection 
with β1,6GlcNAc-T1) was less prevalent. Fucosylation of the core 1 chain was also 
inefficient. We suggest that competition with endogenous sialyltransferases is 
accountable for the decreased conversion rates. 
 
10.3.4 	  Glyco-­‐engineering	  of	  cell	  lines	  
The use of glyco-engineered cell lines for the production of PSGL-1/mIgG2b with 
tailored glycosylation has been successful in our laboratory (Liu et al., 1997), (Liu et 
al., 2005), (Lofling et al., 2002, Lofling et al., 2008, Gustafsson et al., 2011, Holgersson 
et al., 2005, Holgersson and Lofling, 2006, Lofling and Holgersson, 2009), and paper 
II-IV in this thesis). Paper II represents our most ambitious effort so far and 
demonstrates that “rational design” of blood group determinants on different outer core 
chains by transfection of cell lines with plasmids encoding specific glycosyltransferases 
is feasible. Since glycans are secondary gene products, the observed O-glycans on the 
PSGL-1/mIgG2b are the result of competitive actions of both recombinant- and 
endogenous glycosyltransferases. Competition between different glycosyltransferases 
may be overcome by knocking-out the corresponding genes or by using mutant cell 
lines (the Lec2 cell line used in paper II has impaired sialic acid glycosylation). 
Heterogeneity of glycosylation of glycoproteins is commonly observed in recombinant 
therapeutic glycoproteins and on human endogenous glycoproteins (Liu et al., 2008, 
Hossler et al., 2009). This was also seen in paper II where each cell line produced a 
range of O-glycans, of which a major or minor subset carried blood group 
determinants.  
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10.3.5 Mucins	   carrying	   blood	   group	   determinants	   on	   different	   outer	   core	  
saccharide	   chains	   can	   adsorb	   chain	   type-­‐specific	   anti-­‐A	   and	   -­‐B	  
antibodies	  
In paper II, we show that a Sepharose column with the fusion protein carrying A type 1 
determinants adsorb anti-A type 1 and 2 chain-specific antibodies from pooled blood 
group O serum while the absorption of anti-A type 3 and 4 antibodies was less efficient. 
Sepharose columns with A type 1 or type 2 synthetic tetrasaccharides showed similar 
amounts of adsorption. The most efficient adsorption of chain type-specific antibodies 
was seen with a Sepharose column with conjugates of A type 1, 2, 3 and 4 
tetrasaccharides. These results are in agreement with previous studies with tri- and 
tetrasaccharide based Sepharose columns and support the notion that chain-specific 
anti-A or -B antibodies exist in the blood of humans and that their removal from the 
blood is improved by the use of the A and B tetrasaccharide based on type 1-4 
(Lindberg et al., 2012).  
 
10.3.6 Future	  applications	  
The glycan-tailored mucins have already been used as substrates in ELISA assays to 
detect chain type-specific anti-A or -B antibodies (Lindberg et al., 2012). This work is 
ongoing together with optimization work on the immunoadsorption columns and other 
future applications.  The successful transfer of these applications to a clinical setting 
relies on several factors including the feasible production of large quantities of 
correctly glycosylated mucins and the optimization of the suggested protocols.  
 
10.4 Shiga-­‐like	   toxin	   binds	   with	   high	   avidity	   to	   multivalent	   O-­‐linked	  
blood	   group	   P1	   determinants	   on	   mucin	   type	   fusion	   proteins	  
(paper	  III)	  
 
10.4.1 Aim	  and	  background	  
Shiga-like toxin (Stx1/2) producing Escherichia coli (STEC) usually cause diarrhea 
and hemorrhagic colitis but are also associated with the hemolytic uremic syndrome 
(HUS). Cellular attachment and uptake is mediated with the B pentamer of the toxin 
that binds with multiple binding sites to the glycolipid Gb3Cer (blood group Pk antigen, 
Galα1,4Galβ1,4Glcβ-Cer ) on the cell surface (Ling et al., 1998, Mulvey et al., 2003). 
Our hypothesis was that Shiga toxins might bind to the P1 determinant 
(Galα1,4Galβ1,4GlcΝΑcβ), in addition to the Pk determinant since the structures are 
similar. The aim of paper III was to produce a high affinity inhibitor of Shiga toxins 
carrying multiple copies of P1 determinants on the PSGL-1/mIgG2b mucin-type protein.  
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10.4.2 Production	  of	  PSGL-­‐1/mIgG2b	  expressing	  Shiga	  toxin	  receptor	  mimics	  	  
The synthesis pathway of the P1 determinant in glyco-engineered CHO cells (C-PP1) is 
outlined in Figure 15. The α4GalT glycosyltransferase cDNA was cloned from pigeon 
while the other plasmids were available in the laboratory. The fusion protein was 
excreted to the cell medium and purified with affinity and gel filtration 
chromatography. 
 
 
Figure 15 Overview of the synthesis of the terminal P1 blood group determinant on O-glycans carried by 
PSGL-1/mIgG2b produced in glyco-engineered CHO cells (C-PP1) (paper III).  
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10.4.3 PSGL-­‐1/mIgG2b	  carry	  the	  P1	  determinant	  on	  a	  core	  2	  saccharide	  chain	  
PSGL-1/mIgG2b produced in C-PP1 was shown to carry the P1 blood group 
determinant with anti-P1 Western blot and LC-MS2. A significant ion in the LC-MS 
spectrum of O-glycans released from PSGL-1/mIgG2b had a composition 
corresponding to a tentative core 2 structure elongated with two additional hexoses and 
one sialic acid residue. Based on the MS2 fragments and knowledge of the available 
glycosyltransferases in the C-PP1 cell line we suggest that this ion represents the 
Galα1,4Galβ1,4GlcNAcβ1,6(Siaα2,3Gal)GalNAcol.  
 
10.4.4 Stx1	  and	  Stx2	  bind	  with	  high	  affinity	   to	  PSGL-­‐1/mIgG2b	  carrying	  P1	   in	  
multiple	  copies	  
The binding of Shiga-like toxins (Stx1/2) to P1 PSGL-1/mIgG2b (C-PP1) in Western 
blotting was compared to the binding to Pk- and P1 neoglycoconjugates. Stx1 bound 
strongly to Pk-albumin and C-PP1, while only weak binding was observed to P1-
albumin. Stx2 did not bind any of the glycoconjugates in Western blotting.  The 
stronger binding of C-PP1 than P1-albumin may be due to its higher ligand epitope 
density. To further investigate the binding of the Shiga-like toxins a Biacore assay was 
developed where Stx1 or Stx2 was immobilized on a CM5 dextran chip and Pk-albumin 
or C-PP1 were flowed over the surface and binding was measured in real time on a 
Biacore 2000 instrument and plotted in a graph (Figure 16). The SPR technique is 
explained in the Methodological considerations section. The KD value (equilibrium 
dissociation constant) was determined with steady-state calculations on the curves with 
a 1:1 binding model (550-600 s).  Pk-albumin and C-PP1 KD values to Stx1 were in the 
low nanomolar range (39 nM and 16 nM, respectively). The shape of the binding- and 
dissociation curves and the low KD values lead us to suggest that the binding of Pk-
albumin and C-PP1 to Stx1 is multivalent. The binding to Stx2 was markedly reduced 
in comparison. The binding curves had another shape and did not reach equilibrium. 
The KD values of the Stx2 binding were determined from simulated association and 
dissociation curves with a 1:1 binding model (plotted in orange color, C-D). The KD of 
C-PP1 binding to Stx2 was 25 times weaker (379 nM) compared to Stx1 while the KD 
value of Pk-albumin binding to Stx2 was 3 times weaker (101 nM) than for Stx1. 
Previous studies on monovalent Gb3Cer have reported KD levels in the millimolar 
range while the most efficient polyvalent (polymers) inhibitors in vivo have shown KD 
levels in vitro to Stx1 and Stx2 in the low nanomolar range (Gallegos et al., 2012, 
Watanabe et al., 2004). It should be noted that different KD values have been reported 
of Stx1 and Stx2 depending on the analysis method used (Mulvey et al., 2003), 
(Gallegos et al., 2012), (Kitova et al., 2007, Flagler et al., 2010).  
To summarize, C-PP1 is a good binding partner of Stx1 but bind with lower affinity to 
Stx2. Our hypothesis that Shiga toxins might bind to P1, in addition to the Pk 
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determinant was thus confirmed. The potential use of C-PP1 as an inhibitor of Shiga 
toxins is discussed in the separate section, Multivalent PSGL-1/mIgG2b as an inhibitor 
of Shiga toxins and influenza hemagglutinin. 
 
 
 
Figure 16 Biacore sensorgrams demonstrating C-PP1 PSGL-1/mIgG2b and Pk-albumin binding to 
immobilized Stx1 and Stx2 on a CM5 chip. Simulated binding plots in orange color based on a 1:1 
binding model are overlaid the binding curves in A-B (dissociation curves) and C-D (association – and 
dissociation curves). Negative controls with irrelevant glycosylation are shown in red (2700 nM C-P55 in 
A and C, 2700 nM Sia-LacNAc in B and D). Concentrations of injected analytes:  0.14, 0.4, 1.2, 3.7, 11, 
33, 100, 300, 900 and 2700 nM. Stx1 and Stx2 immobilization levels were approximately 2800 and 2000 
RU, respectively. Reference channel- (activated/deactivated) and blank (buffer) subtraction was used to 
reduce buffer bulk effects.  
 
10.5 Avian	  influenza	  H5	  hemagglutinin	  binds	  with	  high	  avidity	  to	  sialic	  
acid	   on	   different	   O-­‐linked	   core	   structures	   on	  
mucin-­‐type	  fusion	  proteins	  (paper	  IV)	  
 
10.5.1 Aim	  and	  background	  
In paper IV we wanted to investigate if PSGL-1/mIgG2b presenting terminal 
Siaα2,3Gal in multiple copies on different saccharide cores may be a good binding 
Analyte: PSGL-1/mIgG2b C-PP1 
Ligand: Stx2 
Analyte: Pk-HSA 
Ligand: Stx2 C D 
Analyte: Pk-HSA 
Ligand: Stx1 B A 
Analyte: PSGL-1/mIgG2b C-PP1 
Ligand: Stx1 
 70 
partner for avian hemagglutinin with the ultimate goal of producing a novel inhibitor 
of highly pathogenic avian influenza such as H5N1. 
 
10.5.2 Production	  of	  PSGL-­‐1/mIgG2b	  in	  different	  cell	  lines	  expressing	  avian	  
influenza	  receptor	  mimics	  	  
In paper IV stable cell lines previously engineered were used. 293-P and C-P55 cell 
lines were established by transfection with a plasmid encoding PSGL-1/mIgG2b ((Liu et 
al., 2005) and paper II). C-PSLex was established by transfecting CHO-K1 cells with 
plasmids encoding PSGL-1/mIgG2b, β1,6GlcNAc-T1 and FUT-VII transferases as 
described previously (Gustafsson and Holgersson, 2006). The fusion protein was 
excreted to the cell medium and purified with affinity and gel filtration 
chromatography.  
 
10.5.3 PSGL-­‐1/mIgG2b	  carry	  avian	  influenza	  receptor	  mimics	  on	  different	  
carbohydrate	  chains	  	  
LC-MS and LC-MS2 analysis on released O-glycans indicated that C-P55 and 293-P 
produce the fusion protein with mostly sialylated core 1 structures 
(Siaα2,3Galβ1,3GalNAcol and minor amounts of Galβ1,3(Siaα2,6)GalNAcol). In 
addition 293-P cells produced a significant ion representing tentative lactosamine on 
core 2 with one or both chains terminated with sialic acid 
(Siaα2,3Galβ1,4GlcNAcβ1,6(Galβ1,3)GalNAcol or  
Galβ1,4GlcNAcβ1,6(Siaα2,3Galβ1,3)GalNAcol). The latter ion is dominant in the LC-
MS spectrum of O-glycans released from PSGL-1/mIgG2b produced in in C-PSLex. 
Western blot with Maackia amurensis lectins (MAL-I and MAL-II) and Sambucus 
nigra agglutinin (SNA) indicated presence of Siaα2,3Gal (MAL-I/II) on the mucins 
derived from all cell lines while no Siaα2,6Gal (SNA) was indicated.  
 
10.5.4 Avian	  influenza	  H5	  hemagglutinin	  binds	  with	  high	  avidity	  to	  	  
PSGL-­‐1/mIgG2b	  carrying	  terminal	  Siaα2,3	  on	  different	  O-­‐linked	  	  
core	  structures	  
The binding of PSGL-1/mIgG2b to recombinant H5 (A/H5N1/Vietnam/1203/2004) was 
measured in a Biacore biosensor assay in a similar manner as in paper III. H5 was 
immobilized to the dextran surface on a CM5 chip and the interaction to PSGL-
1/mIgG2b that was flowed over the surface was recorded and plotted in real-time in a 
sensorgram graph with a Biacore 2000 instrument. The binding curves were 
surprisingly similar between the mucins produced in the different cell lines (Figure 17, 
A-C). Binding of positive control Siaα2,3LAcNAc-albumin was also observed (Figure 
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17, D), while PSGL-1/mIgG2b negative controls with irrelevant glycosylation did not 
bind in a concentration dependent manner (paper IV). The calculated KD (equilibrium 
dissociation constant) values of the mucin-H5 interactions calculated with a 1:1 steady-
state binding model was in the low nanomolar range for all mucins (C-P55 0.8 nM; 
293-P 0.7 nM and C-PSLex 7 nM).  The increased slope at higher concentrations of 
Siaα2,3LAcNAc-albumin (Figure 17, D) indicates heterogeneity in the system. This 
makes KD calculation more uncertain. Excluding the two top concentrations yields a KD 
value that is slightly higher than the values obtained for PSGL-1/mIgG2b but still in the 
low nanomolar range (29 nM). The calculated KD values for the fusion proteins and 
Siaα2,3LAcNAc-albumin may be lower than the “real” KD values because the surfaces 
did not appear to reach saturation even at the highest concentration of injected ligands.  
Taken together the Biacore binding analyses indicate that the mucin-type fusion 
proteins produced in C-P55, 293-P and C-PSLex are good binding partners of 
recombinant avian HA. The low nanomolar affinity is considerably stronger than the 
millimolar range KD values observed between HA and the monovalent binding partners 
(Sauter et al., 1992, Sauter et al., 1989, Toogood et al., 1991).  The binding results give 
an indication that recombinant H5 may bind to Siaα2,3Gal on different carbohydrate 
chains, although we could not show this directly due the presence of several different 
sialylated O-glycans on PSGL-1/mIgG2b produced in each cell line (paper IV). In 
support of this hypothesis a recent study using the same H5 strain as in paper IV 
showed that poly(acrylic acid)amide (PAA) conjugates carrying Siaα2,3 on core 1 and 
type 2 chain (Galβ1,GlcNAcβ) bound with similar affinity in a Biacore single cycle 
kinetics assay (2.9 nM and 1.6 nM respectively) while no binding to Siaα2,6 on type 2 
chain was observed  (Suenaga et al., 2012). Further, in a glycan array experiment H5 
(A/H5N1/Vietnam/1203/2004) bound well to the heavily glycosylated α1-acid 
glycoproteins (orosomucoid, carries both Siaα2,3 and Siaα2,6) and several Siaα2,3Gal 
terminated glycans carrying sulfate substitutions, while no Siaα2,6 binding was 
observed. Taken together, our and other studies indicate that H5 bind to several 
receptors carrying terminal Siaα2,3, while Siaα2,6 binding is absent, and that 
multivalent presentation of the receptor yields a strong binding.  
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Figure 17 Biacore sensorgrams demonstrating PSGL-1/mIgG2b  (produced in C-P55, 293-P and C-
PSLex) and Siaα2,3-LacNAc-albumin binding to immobilized recombinant H5 
(A/H5N1/Vietnam/1203/2004 on a CM5 chip. Reference channel- (activated/deactivated) and blank 
(buffer) subtraction was used to reduce buffer bulk effects.  
 
10.6 PSGL-­‐1/mIgG2b	  as	  a	  multivalent	  inhibitor	  of	  Shiga-­‐like	  toxins	  and	  
avian	  influenza	  
 
10.6.1 Mechanism	  of	  action	  
The concept of multivalent carbohydrate inhibitors of Shiga-like toxins and influenza 
has been demonstrated in several studies but has not resulted in any approved drugs yet 
(Watanabe et al., 2004, Bovin et al., 2004, Matrosovich and Klenk, 2003, Ogata et al., 
2009, Totani et al., 2003, Skehel and Wiley, 2000).The ideal proposed mechanism of 
action is similar for both inhibitors, where the combined effect of competitive 
inhibition and steric hindrance may block the attachment to the cell surface and 
possibly cause aggregation. It remains to be shown if PSGL-1/mIgG2b may have this 
effect on Shiga-like toxins and influenza virus in vitro and in vivo.  
 
10.6.2 Positive	  effect	  of	  inhibitor	  
A Shiga toxin inhibitor may not cure the infection or the HUS complication but buy 
time that allows anti-inflammatory treatments to reduce the cytokine storm that is 
taking place during HUS (Karmali, 2004, Noris et al., 2012). It would be preferable to 
reduce the load of toxin in an early stage of disease, before the toxin may enter the 
blood stream and cause systemic effects. Oral prophylactic use of Shiga toxin inhibitors 
have therefore been proposed (Karmali, 2004). Because an inhibitor of influenza HA 
A 
Analyte: C-P55 
Ligand: H5 B 
Analyte: 293-P 
Ligand: H5 
C 
Analyte: C-PSLex 
Ligand: H5 D 
Analyte: SiaF2,3LacNAc-albumin 
Ligand: H5 
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only blocks the initial phase of the infectious cycle treatment must be prophylactic or in 
early phase of disease. However, granted the inhibitor is highly efficient, the complete 
blocking of infection may protect both individuals and limit human-to-human spread. 
In contrast NA inhibitors that mainly inhibit the release of influenza virus during 
budding alleviate disease symptoms but does not limit human to human spread.  
 
10.6.3 Achieving	  high	  concentration	  of	  inhibitor	  in	  a	  large	  surface	  area	  is	  a	  
challenge	  
The surface area of the intestine is very large which may limit the inhibition of the 
Shiga-like toxin in the gut. By using a multivalent inhibitor, the local concentration can 
increase dramatically compared to a monovalent inhibitor. In animal models of STEC 
infections oral treatment with linear acrylamide polymers with highly clustered Gb3 
trisaccharides bound to both Stx1 and Stx2 and decreased the disease symptoms 
(Watanabe et al., 2004). The monovalent inhibitor of Shiga toxin, Synsorb-Pk, notably 
failed in clinical trials (Trachtman et al., 2003).  In a similar manner it is conceivably 
difficult to prevent even a single virus from attaching to cells in the respiratory tract. In 
contrast, the eye surface area is only ~2 cm2 (compare with ~50 cm2 of the proximal 
airways and ~2 m2 of the distal airways) and might thus be a more manageable area to 
protect if topical treatment with anti-influenza drugs is envisioned (Tsubota and 
Nakamori, 1995). Since the eyes may be an entrance port of highly pathogenic avian 
influenza there is indeed an interest in protecting the eyes (Belser et al., 2012) 
(Fouchier et al., 2004). Inhibition of oculotropic adenoviruses with multivalent 
constructs carrying sialic acid has been successfully shown in vitro (Aplander et al., 
2011, Spjut et al., 2011, Johansson et al., 2007).  
 
10.6.4 In	  vivo	  considerations	  
It has been observed that the Shiga toxin is not free in the circulation but is mainly 
bound to polymorphonuclear leukocytes (Brigotti et al., 2011). It remains to be seen if 
this limits the use of Shiga toxin inhibitors in vivo. By inhibiting influenza HA with an 
identical receptor analogue the risk of HA escape mutations is decreased (Bovin et al., 
2004), but at the same time the inhibitor may be destroyed by NA hydrolysis. 
Modification of sialic acid on multivalent inhibitors, such as acetylation may prevent 
hydrolysis short term for some strains, but will likely generate escape mutants (Pritchett 
and Paulson, 1989). The concentration of inhibitor must therefore likely be high in 
order to overwhelm the binding of HA and hydrolysis activity of NA.  This may be 
accomplished by increasing the concentration or the size and substitution grade of the 
inhibitor. It should be realized that the influenza virus binding (HA) and release (NA) 
molecules act in concert on the virus surface. Studies of NA inhibitor resistant 
influenza have indicated a weaker binding of HA to sialic acid receptors and 
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consequently a reduced role of NA during release of novel virus particles (Pritchett and 
Paulson, 1989). The combined use of several antiviral drugs such as HA and NA 
inhibitors may thus be needed in the future in order to reduce the rate of escape 
mutations (Barik, 2012). The effect of a multivalent inhibitor in vivo may not be easy to 
predict by in vitro experiments. Mammen et al previously showed that a polyvalent 
inhibitor bound poorly to HA-trimers but was an efficient inhibitor of influenza virus 
hemagglutination (Mammen et al., 1998). Binding of a single inhibitory molecule may 
be enough to cover the viral surface with the polymer that sterically prevents the virus 
from cross-linking erythrocytes (hemagglutination). Thus steric inhibition may be more 
important than competitive inhibition. In order to avoid unwanted side effects, non-
human carbohydrates should not be present on inhibitors that are exposed to the 
immune system. Comprehensive structural characterization of the glycosylation is 
therefore needed on all licensed therapeutic glycoproteins.  The Fc-portion of PSGL-
1/mIgG2b contributes to a long half-life in circulation but care must be taken to avoid 
unwanted effector functions.  
 
10.6.5 Other	  application	  of	  multivalent	  carbohydrate	  inhibitors	  
In addition to synthetic Gb3 mimics, other suggested inhibitors of Shiga toxins are 
probiotic bacteria expressing Gb3 on the surface and monoclonal antibodies (James, 
1992, MacConnachie and Todd, 2004). A dialyzer with immobilized glycoconjugate 
polymers for removal of Shiga toxin has been developed (Miyagawa et al., 2006). The 
concept has only been tested in vitro so far, though.  Other possible applications of 
PSGL-1/mIgG2b expressing the P1 epitope include the inhibition of P-fimbriated 
uropathogenic E coli, Pseudomonas aeruginosa (PA-I lectin), and Staphylococcus 
aureus (enterotoxin B) since the P1 determinant is the receptor of these microbes and 
toxins (Bock et al., 1985, Gilboa-Garber et al., 1994),(Tikkanen et al., 1995, Tikkanen 
et al., 1996, Chatterjee et al., 1995). PSGL-1/mIgG2b that carries multivalent sialic acid 
may also be a suitable inhibitor of oculotropic adenoviruses (Aplander et al., 2011, 
Spjut et al., 2011, Johansson et al., 2007). 
 
10.6.6 PSGL-­‐1/mIgG2b	  compared	  to	  chemical	  and	  naturally	  occurring	  
inhibitors	  
Multivalency may be achieved by both organic chemistry and molecular biology. 
Chemists may be able to effectively synthesize homogenous polymers with high 
substitution grades with tailored scaffolds; however the synthesis of complex 
carbohydrates remains challenging. Glyco-engineering of CHO cells offers the 
advantage of producing multivalent glycoproteins with longer carbohydrate chains 
while chemical synthesis is often limited to tri- or tetrasaccharides. Longer 
carbohydrate chains may confer more specific binding compared to trisaccharides. 
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Indeed, it was shown that blood group A/B on type 1-4 tetrasaccharides were more 
efficient adsorbers of anti-A/B chain type-specific antibodies than A and B 
trisaccharide determinants (Lindberg et al., 2012).  Paper II-IV represents examples of 
rational glycan design of PSGL-1/mIgG2b with specific glycosylation for specific 
purposes. Another possible strategy may be to make use of naturally occurring 
glycoproteins, such as those found in milk. The glycoproteins may be suitable for 
several applications, including inhibition of toxins or microbial attachment (Rasooly et 
al., 2012, Gustafsson et al., 2006). Challenges for recombinant glycoprotein inhibitors 
include the high costs and the comprehensive structural characterization that is needed 
to ensure a homogenous reproducible product. 
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11 Conclusions 
• Analysis of the recombinant PSGL-1/mIgG2b mucin-type fusion protein in 
Spodoptera frugiperda (Sf9) and Trichoplusia ni (Hi-5) cells revealed that the 
O-glycosylation of these cells is more abundant and complex than previously 
reported (paper I).  
o The abundance of non-human N- and O-linked glycans produced by 
Hi-5 and Sf9 insect cells may limit their use as an expression system 
of therapeutic proteins 
• CHO cells were successfully glyco-engineered in order to produce PSGL-
1/mIgG2b that carried O-linked blood group A- and B determinants on type 1, 
type 2 and type 3 outer core saccharide chains (paper II).  
o We showed that the mucins could adsorb chain type-specific 
antibodies from blood. 
o In the future the mucins may therefore be used in	  immunoadsorption 
columns to remove chain-specific anti-A and anti-B antibodies prior 
to organ transplantation and as substrates for the quantification and 
specificity-determination of ABO antibodies. 
• PSGL-1/mIgG2b carrying multivalent O-linked carbohydrate receptors of 
Shiga-like toxin and avian influenza H5 was successfully produced (paper III 
and IV).  
o PSGL-1/mIgG2b carrying the P1 determinant bound with low 
nanomolar affinity to Stx1 in a Biacore assay, while Stx2 bound with 
lower affinity. 
o PSGL-1/mIgG2b carrying Siaα2,3Gal on mainly core 1 or lactosamine 
bound with similar low nanomloar affinities to avian H5 
hemagglutinin.	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12 	  Future	  projects	  
12.1 Paper	  I	  
The complete O-glycome and N-glycome determined from total cell extracts of Sf9 and 
Hi-5 cells would be of general interest but was beyond the scope of paper I. A deeper 
understanding- and manipulation of the glycosylation machinery of these cell lines 
would also benefit from the complete genome sequence as demonstrated previously for 
silk worm (Xiang et al., 2010, Li et al., 2012, Xia et al., 2009). As of today it is not 
clear which enzymes that synthetize most of the detected structures and the 
substitutions detected in paper I. Recent progress in transient and stable “knock-down” 
and “knock-out” technologies of specific genes may prove to be powerful techniques to 
study the action of specific glycosyltransferases (Kim et al., 2012, Malphettes et al., 
2010). In paper I a general purpose culture medium was used (with serum), it may 
therefore be interesting to compare the glycosylation pattern observed with other 
defined cell media (such as serum-free medium), although the cell culture medium 
effect on glycosylation have been explored previously (Ikonomou et al., 2003, 
Drugmand et al., 2012) 
 
12.2 Paper	  II	  
Different applications of the mucin-type fusion proteins carrying blood group antigens 
are being explored such as immunoadsorbers and ELISA substrates.  
Future work in this field of glyco-engineering will benefit greatly from the recent 
initiative that provides expression constructs for more than 80% of all mammalian 
glycosylation enzymes for free to the research community (Repository of Glyco-
Enzyme Expression http://glycoenzymes.ccrc.uga.edu/, last accessed April 17 2013). 
 
12.3 Paper	  III	  and	  IV	  
Additional Biacore experiments with different set-ups (that is immobilize PSGL-
1/mIgG2b and flow Shiga toxin or hemagglutinin over the surface) and ELISA assays 
may be used to validate the binding data from paper III and IV. Immobilizing PSGL-
1/mIgG2b would also facilitate the evaluation of PSGL-1/mIgG2b as an inhibitor, since a 
pre-mixing step before injection may then be performed with different amounts of 
monovalent binding partners or PSGL-1/mIgG2b. The ability of PSGL-1/mIgG2b to 
inhibit erythrocyte hemagglutination caused by influenza virus may also be used as 
method to evaluate the inhibitory potential. The protective effect of PSGL-1/mIgG2b on 
Shiga toxin sensitive Vero cells or influenza virus sensitive MDCK cells may also be 
necessary future in vitro assays.  
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